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Stellingen 
1. Een goed proefdiermodel voor het effect van cholesterol en vetzuren op net 
lipoproteinenmetabolisme hoeft niet noodzakelijk ook een goed proefdiermodel 
te zijn om het mechanisme van cafestol te bestuderen. (dit proefschrift). 
2. In apolipoproteine E*3-Leiden transgene muizen verhoogt cafestol het LDL 
cholesterol primairdoor remming van de galzuursynthese (dit proefschrift). 
3. Cafestol verhoogt het serum triglyceriden en het LDL cholesterol gehalte 
onafhankelijk van elkaar (dit proefschrift). 
4. In mechanistisch onderzoek naar effecten van stoffen op het lipoproteinen 
metabolisme is informatie over veranderingen in lipoproteinen (-subfracties) 
minstens zo belangrijk als informatie over veranderingen in lipiden. 
5. Het is vooralsnog niet bewezen dat voedingsvezel beschermt tegen het optreden 
van colonkanker (o.a. Fuchs etal., NEJM 1999;340:169-176). 
6. De ongenuanceerde uitspraken over voeding en gezondheid in populaire 
magazines impliceren dat een voedingskundige zich naast de rol van 
'wetenschapper' beter zou moeten richten op de rol van 'voorlichter'. 
7. De publieke opinie rond de introductie van genetisch gemodificeerde produkten 
in Groot-Brittannie wordt gemanipuleerd door de media. 
8. Gebrek aan kennis over het gebruik van proefdieren in medisch onderzoek is 
voor een groot deel verantwoordelijk voor een negatieve houding ten opzichte 
van dierexperimenteel onderzoek (New Scientist, 22 mei 1999). 
9. De tijd die nodig is voor het afronden van een manuscript is positief gecorreleerd 
met het aantal co-auteurs. 
10. Personen van dezelfde sexe gaan zich doorgaans sexe-stereotieper gedragen 
als ze onder elkaar zijn (Psychologie, maart 1999). 
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Abstract 
Mechanistic studies on the lipid-raising coffee diterpenes cafestol and kahweol 
in monkeys, mice and man 
PhD thesis by Baukje de Roos, Division of Human Nutrition & Epidemiology, 
Wageningen University, Wageningen, The Netherlands. 
Cafestol and kahweol are lipid-raising diterpenes present in unfiltered coffee. The 
objective of this thesis was to study their lipid-raising action in man. Unravelling this 
action might lead to new insights into the regulation of serum cholesterol levels. 
We first studied the absorption and urinary excretion of cafestol and kahweol in 
eight ileostomy volunteers. About 70% of the consumed cafestol and kahweol was 
absorbed and thus available for raising serum lipids in humans. Only 1.2% of the 
diterpenes was subsequently excreted as a conjugate of glucuronic acid or sulphate 
in urine, suggestive for an extensive metabolism of coffee diterpenes. 
We then searched for an animal model to study the mechanism of action of 
cafestol and kahweol. In African green monkeys, both diterpenes raised total 
cholesterol less pronounced than in man. Unlike humans, the rise in cholesterol was 
predominantly due to a rise in HDL cholesterol rather than LDL cholesterol. In 
apolipoprotein E*3-Leiden mice, cafestol and kahweol increased total cholesterol with 
61% after eight weeks of treatment. The increase in total cholesterol was mainly due 
to a rise in VLDL and IDL cholesterol. After three weeks of treatment, total 
cholesterol was increased due to suppression of bile acid synthesis, which caused a 
decreased expression of the LDL receptor. In addition, VLDL became enriched in 
cholesteryl esters. 
Two mechanistic studies were performed in healthy human subjects. Consumption 
of cafetiere (French-press) coffee increased CETP activity by 15% after 12 weeks of 
intervention. The increase in CETP activity clearly preceded the increase in LDL 
cholesterol. Cafestol increased serum triglycerides by an 80% increase in the 
production rate of VLDLi apolipoprotein B after two weeks of intervention. This 
resulted in an increased amount of VLDLi particles in the circulation. Cafestol did not 
change the composition of VLDLT. VLDL2 became enriched with cholesteryl esters. 
In conclusion, cafestol first increases plasma triglycerides by increasing the 
production rate of VLDLi apolipoprotein B. The subsequent rise in LDL cholesterol 
might be due to suppression of bile acid synthesis, which probably leads to down-
regulation of the LDL receptor and/or to an enrichment of VLDL2 with cholesteryl 
esters. The mechanisms of action that raise plasma cholesterol and plasma 
triglycerides in humans might be regulated independently in the liver. 
Abbreviations 
ACAT 
ALAT 
ApoB 
ApoE 
C 
CDC 
CE 
CETP 
D3-leucine 
DC 
DMSO 
GAPDH 
HDC 
HDL 
HL 
HMG-CoA 
IDL 
LC 
LCAT 
LDL 
LDLR 
LpL 
LRP 
MC 
MTP 
PABA 
PLTP 
PPAR 
RER 
SER 
Sf 
SREBP 
UDC 
VLDL 
pVLDL 
acyl-coenzyme A:cholesterol-acyltransferase 
alanine aminotransferase 
apolipoprotein B 
apolipoprotein E 
cholic acid 
chenodeoxycholic acid 
cholesteryl ester 
cholesteryl ester transfer protein 
L-[5,5,5-2H3]leucine 
deoxycholic acid 
dimethylsulfoxide 
glyceraldehyde-3-phosphate 
hyodeoxycholic acid 
high density lipoprotein 
hepatic lipase 
3-hydroxy-3-methylglutaryl coenzyme A 
intermediate density lipoprotein 
litocholic acid 
lecithin:cholesterol acyltransferase 
low density lipoprotein 
LDL receptor 
lipoprotein lipase 
LDL receptor-related protein 
muricholic acid 
microsomal triglyceride transfer protein 
para-amino benzoic acid 
phospholipid transfer protein 
peroxisome proliferator-activated receptor 
rough endoplasmic reticulum 
smooth endoplasmic reticulum 
Svedbergs flotation rate 
sterol regulatory element binding protein 
ursodeoxycholic acid 
very low density lipoprotein 
p-migrating very low density lipoprotein 
Contents 
Chapter 1: Introduction 9 
Possible mechanisms underlying the cholesterol-raising effect of the coffee 
diterpene cafestol 
Chapter 2 17 
Absorption and urinary excretion of the coffee diterpenes cafestol and 
kahweol in healthy ileostomy volunteers 
Chapter 3 35 
Validity of animal models for the cholesterol-raising effects of coffee 
diterpenes in humans 
Chapter 4 47 
Cafestol, the cholesterol-raising factor in boiled coffee, increases serum 
cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by 
suppression of bile acid synthesis 
Chapter 5 67 
Consumption of cafetiere coffee raises cholesteryl ester transfer protein 
activity levels before LDL cholesterol in normolipidemic subjects 
Chapter 6 77 
The coffee diterpene cafestol increases plasma triglycerides by increasing 
the production rate of large very low density lipoprotein apolipoprotein B in 
normolipidemic subjects 
Chapter 7: General discussion 93 
Summary 107 
Samenvatting 111 
Dankwoord 115 
Curriculum Vitae 117 
List of publications 119 
1 
General introduction 
Possible mechanisms underlying the cholesterol-
raising effect of the coffee diterpene cafestol 
Baukje de Roos and Martijn B. Katan. Current Opinion in Lipidology 1999; 10:41-45. 
Abstract 
Cafestol, a coffee diterpene present in unfiltered coffee brews, potently raises 
serum lipids in humans. The mechanism through which this dietary compound 
influences lipoprotein metabolism is largely unknown. Unravelling the mechanism of 
action might lead to new insights into the regulation of serum cholesterol levels in 
humans. This review summarises ways in which cafestol may act on serum lipids. 
Chapter 1 
Introduction: coffee diterpenes raise serum lipids in humans 
Cafestol and kahweol are fat-soluble diterpenes in coffee beans. They are present 
in commercially important blends of Arabica and Robusta Coffea species, as well as 
in wild African Coffea species (1). Unfiltered coffee brews such as Scandinavian 
boiled coffee, cafetiere coffee, and Turkish coffee contain 3-6 mg of each diterpene 
per cup (2;3). Cafestol and kahweol potently raise serum cholesterol and triglycerides 
in humans (4;5). Of the two diterpenes, cafestol is responsible for more than 80% of 
the effect on serum lipids (6). This review therefore focuses on cafestol and its 
possible mode of action. 
Cafestol is the most potent cholesterol-elevating compound known. Each 10 mg of 
cafestol increases serum cholesterol by 0.13 mmol/L and serum triglycerides by 0.08 
mmol/L after consumption for four weeks (7). When 22 volunteers consumed 0.9 L of 
cafetiere coffee per day (8), serum cholesterol reached a maximum increase of 17% 
after eight to twelve weeks. About 80% of the rise in total cholesterol was due to LDL 
cholesterol, and the rest was due to a rise in VLDL cholesterol. In this study cafetiere 
coffee did not affect serum HDL cholesterol. However, in other studies HDL 
decreased slightly with cafestol intake (5;6;9). Serum triglycerides increased by 26% 
after two to four weeks of cafetiere coffee, but they were back to baseline after 24 
weeks (8). Thus the effect on triglycerides is transient while the effect on LDL 
cholesterol is permanent. This is in good agreement with epidemiological 
observations (5;10;11). A number of mechanisms can be involved to explain the 
effect of cafestol on lipoproteins. The most important candidates are discussed 
below. 
Proposed mechanism: the SREBP pathway 
Any proposed mechanism should explain both a transient rise in VLDL and a 
permanent rise in LDL in subjects consuming cafestol. Both effects could 
hypothetically be explained by a primary effect of cafestol on the sterol regulatory 
element binding proteins (SREPB)-pathway. SREBP are membrane bound 
transcription factors, which are important regulators of cholesterol biosynthesis in 
humans. Sterols induce a proteolytic cleavage of the NH2-terminal domain of the 
SREBP. This domain binds subsequently to specific DNA sequences, by which it can 
modulate the transcription of certain genes involved in lipid metabolism, such as 
genes for HMG-CoA reductase, lipoprotein lipase and the LDL receptor (12). 
The rise in VLDL and LDL could now be explained as follows (figure 1 A). 
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Figure 1. Three proposed mechanisms for the action of cafestol on lipoprotein metabolism. AC AT: 
acyl-CoA:cholesterol acyltransferase; HMG-CoA: 3-hydroxy-3-methyl-glutaryl CoA; VLDL: very low 
density lipoproteins; LDL: low density lipoproteins; HDL: high density lipoproteins; CETP: cholesterol 
ester transfer protein; PLTP: phospholipid transfer protein; PPARs: peroxisome proliferator-activated 
receptors. 
An effect of cafestol on SREBP may be generated by modulating the pool of free 
cholesterol in the liver cell. For example, cafestol might inhibit cholesterol acyl-
CoAxholesterol acyltransferase (ACAT) activity, and thereby the conversion of 
unesterified cholesterol into its cholesterol ester. Cafestol indeed decreased 
cholesterol esterification in CaCo-2 cells (13). However, it increased cholesterol 
esterification in human skin fibroblasts (14). Cafestol did not affect cholesterol 
esterification in HepG2-cells, suggesting that ACAT activity was not modified (15) 
(figure 2). Thus it is unclear whether cafestol affects the pool of free cholesterol 
through modulation of ACAT. Alternatively, cafestol might inhibit the activity of 
cholesterol 7oc-hydroxylase, a rate-limiting enzyme in the conversion of cholesterol 
into bile acids. Cafestol did not affect bile acid formation in HepG2-cells (15) (figure 
2). However, cafestol decreased bile acid mass production in rat hepatocytes in a 
dose-dependent matter. In addition, cafestol reduced the activity of both cholesterol 
7oc-hydroxylase and sterol 27-hydroxylase. These reductions paralleled a reduction in 
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cholesterol 7a-hydroxylase and in sterol 27-hydroxylase mRNA (16). Thus 
suppression of bile acid synthesis may explain the cholesterol-raising effects of 
cafestol. Therefore, it would be interesting to study changes in bile acid mass 
production in vivo. 
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Figure 2. Summary of the effects of cafestol on cholesterol metabolism in CaCo-2 cells (a human 
colon adenoma cell line), in fibroblasts (human skin fibroblast cells), in HepG2 cells (a human 
hepatoma cell line), and in rat hepatocytes. LDL: low density lipoproteins; ACAT: acyl-CoAxholesterol 
acyltransferase; HMG-CoA: 3-hydroxy-3-methyl-glutaryl CoA. 
When the pool of free cholesterol in the liver cell increases, the activity of SREBP 
will be reduced (12). This may result in a decreased transcription of the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA reductase) gene. HMG-CoA reductase is a 
key enzyme involved in the synthesis of cholesterol. However, both in vivo and in 
vitro studies do not provide clear evidence for a cafestol-induced decreased 
transcription of this enzyme. Boiled coffee did not affect the ratio of serum 
lathosterol:total cholesterol - a measure of whole-body cholesterol synthesis - in 
humans (17). Cafestol reduced HMG-CoA reductase mRNA in rat hepatocytes (16) 
and in human skin fibroblasts (14). However, cafestol did not affect cholesterol 
synthesis in HepG2 cells (15), while it increased cholesterol synthesis in CaCo-2 
cells (13) (figure 2). Alternatively, down-regulation of SREBP activity may result in a 
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decreased transcription of the lipoprotein lipase gene. Subsequently, triglyceride-rich 
VLDL can not efficiently be cleared from the plasma by lipoprotein lipase, and plasma 
VLDL will increase. An alternative explanation for increased VLDL concentrations 
might be an elevated VLDL production rate. A subsequent recovery in lipoprotein 
lipase activity might explain why triglycerides eventually return to baseline. However, 
the role of lipoprotein lipase in the mechanism of action of cafestol has not been 
established yet. Down-regulation of SREBP activity may also result in a decreased 
transcription of the LDL receptor gene. As a consequence, LDL receptor activity is 
suppressed, uptake of LDL from the plasma is impaired and plasma cholesterol will 
increase (18). Results on the ability of cafestol to modify LDL receptor activity in vitro 
are however contradictory. Cafestol decreased LDL receptor mRNA in rat 
hepatocytes (16), whereas LDL receptor mRNA was not affected in human skin 
fibroblasts (14). However, cafestol reduced the uptake of radio-labelled LDL and the 
number of LDL receptors in human skin fibroblasts (14) and in HepG2 cells (15). The 
authors concluded that down-regulation of the LDL receptor by post-transcriptional 
mechanisms might explain the effects of cafestol on plasma cholesterol. Unlike the 
previously mentioned cell lines, cafestol increased the uptake of radio-labelled LDL 
and the amount of LDL receptor mRNA in CaCo-2 cells (13) (figure 2). Since in vitro 
studies do not provide consistent evidence for involvement of the LDL receptor in the 
mechanism of cafestol, an animal model to study LDL receptor expression in vivo 
would be very useful. 
Proposed mechanism: cholesterol ester transfer proteins 
Another mechanism that might explain the effects of cafestol on lipoprotein 
metabolism is via cholesterol ester transfer proteins. Cafestol might elevate plasma 
LDL and VLDL cholesterol and decrease HDL cholesterol by changing their 
composition. Cafestol could lead to an enrichment of LDL with cholesteryl esters, 
which results in elevated LDL cholesterol levels. This change in lipoprotein 
composition might be mediated by an increased activity of cholesteryl-ester transfer 
proteins (CETP) and phospholipid transfer protein (PLTP) (figure 1B). 
In humans, consumption of diterpenes increased the activity of CETP and PLTP 
and decreased the activity of lecithinxholesterol acyltransferase (LCAT) (19). 
However, consumption of unfiltered coffee did not affect lipoprotein composition, 
although apolipoprotein B100 was slightly increased (de Roos, van Tol, unpublished 
results). Two other studies also showed a similar rise in apolipoprotein B100 (17;20). 
The increase in VLDL and LDL cholesterol appears thus more likely due to changes 
in the number of lipoprotein particles than to a change in lipoprotein composition. 
Therefore, the role of CETP and PLTP in the mechanism of action of cafestol is 
doubtful. 
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Proposed mechanism via PPARs 
A third mechanism by which cafestol might affect serum triglycerides and LDL 
cholesterol is via peroxisome proliferator-activated receptors (PPARs) (figure 1C). 
PPARs can be considered as key messengers which are responsible for the 
translation of nutritional, pharmacological and metabolic stimuli into changes in the 
expression of genes. PPARs compose a subfamily of the nuclear hormone receptors. 
To date, three different types of PPARs - a, p, and y - have been identified. PPARoc 
plays a key role in the p-oxidation of fatty acids, while PPARy is involved in the 
storage of fatty acids. They are activated by various fatty acid metabolites as well as 
by several drugs. Activated PPARs heterodimerise with another nuclear receptor: the 
retinoid X receptor. This complex will bind to specific peroxisome proliferator 
response elements, by which they alter the transcription of target genes (21). We 
investigated whether cafestol binds to PPARs and whether cafestol changes 
transcription mediated by PPARoc, p\ and y. 
We established that cafestol in concentrations up to 10 |iM did not cause a 
detectable displacement of specific radioligands for PPARoc, p, and y from any of its 
three receptors (K. MacNaul, D. Moller, unpublished results). High concentrations of 
cafestol, i.e. up to 20 |j.M, inhibited transcription of a Gal4-responsive reporter gene in 
transfected cells expressing chimaeric Gal4-PPAR constructs for each of the three 
receptor isoforms (D. Moller, J. Berger, unpublished results). However, given the lack 
of binding and the fact that all 3 PPARs were affected in a similar fashion, we 
interpret this to be a non-specific cell toxicity effect. Therefore, it appears unlikely that 
PPARs play a role in the mechanism of action of cafestol. 
Conclusion 
At this moment, the most plausible mechanism by which cafestol elevates 
cholesterol in humans is via the SREBP-pathway. However, data from in vitro studies 
are inconsistent and indicate that cafestol or its metabolites may act differently in 
various cell types. A different regulation of cholesterol levels and the LDL receptor 
may be caused by the fact that mucosal cells (CaCo-2 cells), fibroblasts and liver 
cells (HepG2 cells and rat hepatocytes) have different metabolic functions. Because 
of these conflicting results from in vitro studies, and especially because of the sparse 
knowledge we have on the mechanism of cafestol in man, we can not deduce which 
finding might be applicable in vivo. We thus need to know how cafestol affects 
lipoprotein composition, synthesis, and degradation in humans. In addition, it would 
be interesting to know how cafestol is transported in the plasma, as well as how it is 
metabolised in the liver. Then, we might be able to define a model - either in vitro or 
in vivo - which can answer questions on the action of cafestol. 
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Objective and outline of this thesis 
The objective of our research was to study the mechanism of action of cafestol 
(and kahweol) in man. 
We first assessed which part of the consumed coffee diterpenes is absorbed in 
healthy ileostomy volunteers and thus available for raising serum lipoproteins in 
humans (Chapter 2). Considering the effects of cafestol and kahweol on lipoprotein 
metabolism and serum liver enzymes, it appears likely that the liver is the target 
organ for their action. In this case, the possibilities for mechanistic studies in humans 
are limited, and an animal model would therefore be useful. Chapter 3 reviews the 
validity of various animal models for the cholesterol-raising effects of coffee 
diterpenes in humans. This chapter also describes the effects of cafestol and 
kahweol on serum lipoproteins in African green monkeys, an animal model which 
shows many similarities with humans in the effects of dietary cholesterol and fatty 
acids on plasma lipoproteins. Chapter 4 continues with the effects of cafestol and 
kahweol on serum lipoproteins in two hyperlipidaemic mouse strains: heterozygous 
LDL receptor knock-out mice and apolipoprotein E*3-Leiden transgenic mice. In the 
latter mouse strain we subsequently performed studies on the mechanism of the 
cholesterol-raising effect. The following two chapters describe two mechanistic 
studies in humans. We first studied the possible involvement of cholesteryl ester 
transfer proteins (CETP) in the cholesterol-raising action of cafetiere coffee (Chapter 
5). We then determined the production and fractional catabolic rate of large very low 
density lipoprotein (Vl-Dl^) apolipoprotein B in order to explain the triglyceride-raising 
effect of cafestol (Chapter 6). Finally, the main outcomes of the mechanistic studies 
with cafestol are discussed in Chapter 7. 
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2 
Absorption and urinary excretion of the coffee 
diterpenes cafestol and kahweol in healthy 
ileostomy volunteers 
Baukje de Roos, Saskia Meyboom, Truus G. Kosmeijer-Schuil and Martijn B. Katan. 
Journal of Internal Medicine 1998; 244:451-460. 
Abstract 
The objective of this study was to determine the absorption and urinary excretion 
of the cholesterol-raising coffee diterpenes cafestol and kahweol in man. Nine 
healthy ileostomists consumed a dose of 1, 2, or 3 cups of French-press coffee 
together with a standardised breakfast on three separate days in random order. 
Subsequently, ileostomy effluent was collected for 14 h and urine for 24 h. We 
measured absorption and urinary excretion of diterpenes and the stability of cafestol 
and kahweol was also assessed under simulated gastro-intestinal tract conditions. 
Corrected mean absorption expressed as percentage of the amount consumed and 
as percentage of the amount entering the duodenum was 67% and 88%, 
respectively, for cafestol, and 72% and 93%, respectively, for kahweol. We found 
losses of diterpenes during incubation in vitro with gastric juice (cafestol 24%, 
kahweol 32%), during storage with ileostomy effluent (cafestol 18%, kahweol 12%), 
and during freeze-drying (cafestol 26%, kahweol 32%). Mean excretion of 
glucuronidated plus sulphated conjugates in urine was 1.2% of the ingested amount 
for cafestol and 0.4% of the ingested amount for kahweol. In conclusion, about 70% 
of the ingested cafestol and kahweol is absorbed in ileostomy volunteers. Possibly, 
undetected metabolites are present in ileostomy effluent, resulting in lower 
absorption percentages. Only a small part of the diterpenes is excreted as a 
conjugate of glucuronic acid or sulphate in urine. Therefore these compounds are 
extensively metabolised in the human body. 
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Introduction 
Cafestol and kahweol (figure 1) are naturally-occurring diterpenes in coffee beans 
(1), where they are present as fatty esters, mainly of palmitic and linoleic acids (2). 
They are responsible for the low density lipoproteins (LDL) and very low density 
lipoproteins (VLDL)-raising effect of Scandinavian-type boiled coffee (3;4), which 
contains 3-4 mg of each per cup (1). Levels of diterpenes are also high in other 
unfiltered coffee brews such as Turkish/Greek and French-press or cafetiere coffee 
(1). The LDL- and VLDL raising effect of cafestol and kahweol seems to be unique 
for humans: serum lipids in various animal models did not respond to the two 
diterpenes (5). 
\ ^ \ ^ 
kahweol 
Figure 1. Structure of the coffee diterpenes cafestol and kahweol. Diterpenes occur in coffee beans 
mainly esterified to fatty acids at the C16 or C17 position. 
In humans, cafestol appears to be mainly responsible for the effects on serum 
lipids (5;6). A meta-analysis on eleven trials showed that a daily dose of 10 mg of 
cafestol for four weeks raised serum cholesterol by 0.13 mmol/L, while kahweol 
raised serum cholesterol by 0.02 mmol/L. About 80% of the rise in serum cholesterol 
was accounted for by LDL cholesterol. A daily dose of 10 mg of cafestol or kahweol 
for four to six weeks raised serum triglycerides by 0.08 mmol/L and 0.01 mmol/L, 
respectively. Most of the rise in serum triglycerides subsides with chronic intake of 
coffee diterpenes (5). Both cafestol and kahweol also appear to affect liver cell 
functioning in humans: each 10 mg of cafestol or kahweol per day increased alanine 
aminotransferase by 2-3 U/L after four weeks (5). The different capacities of cafestol 
and kahweol to raise serum lipids or serum liver enzymes indicate that possibly two 
distinct mechanisms of action are involved. 
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Knowledge about the absorption and the mechanisms of action of these coffee 
diterpenes in humans is limited. In vitro studies suggest that the coffee diterpenes 
decrease receptor-mediated uptake of LDL cholesterol (7;8). A lower hepatic uptake 
of LDL cholesterol may contribute to the cholesterol-raising effect of cafestol 
observed in humans. Absorption values are now required to assess which part of the 
consumed diterpenes is actually responsible for the rise in serum lipids. Factors such 
as dose might influence absorption, and thus the effects observed. In addition, 
absorption values indicate which part of the consumed diterpenes are unabsorbed 
and thus enter the colon, where they might have beneficial effects: intake of coffee 
diterpenes reduced the frequency of adenocarcinoma of the colon in rats (9), and in 
some human epidemiological studies a lower incidence of colon cancer with coffee 
intake was found (10). More insight into the metabolism of cafestol and kahweol in 
the human body might lead us to the compound that actually raises serum lipids. This 
active compound could be cafestol or kahweol, but it could also be a metabolite. 
Such insights would facilitate further studies of the mechanism of action. 
We assessed the absorption of cafestol and kahweol from increasing doses of 
French-press coffee by measuring coffee diterpenes in ileostomy effluent of healthy 
ileostomy volunteers. We also provide evidence for the excretion of conjugated 
cafestol and kahweol metabolites in urine. 
Subjects and methods 
We obtained prior approval for the experiment from the Medical Ethical Committee 
of the Department of Human Nutrition, Wageningen University. 
Subjects 
We recruited subjects by writing to members of the Dutch association of 
ileostomists and by approaching volunteers from a previous study (11). Thirteen 
subjects filled out a general and a medical questionnaire and blood samples were 
taken for standard laboratory assays. Exclusion criteria were: signs of Crohn's 
disease or malabsorption, resection of more than 50 cm of the terminal ileum, an 
ileostomy that did not function properly, a history of hepatobiliary disease, renal 
disease or diabetes, use of drugs influencing gastro-intestinal transit, present illness, 
pregnancy or lactation, a serum haemoglobin concentration of less than 8.6 mmol/L 
for men or less than 7.4 mmol/L for women, serum cholesterol levels of more than 
8.0 mmol/L, triglyceride levels of more than 2.37 mmol/L, or ALT levels exceeding the 
upper limit of normal. We checked urine samples for protein and glucose. The 
medical questionnaires and the results of the blood tests were judged by an 
independent gastro-enterologist. Four subjects were excluded from this study 
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because of Crohn's disease (n=1), liver and gall bladder disease (n=1), small 
intestine disease (n=1) or removal of more than 50 cm of the terminal ileum (n=1). 
Nine subjects (4 men and 5 women) with a mean age of 60 years (range 43-71 
years) and mean (±SD) body mass index of 26.8±3.0 kg/m2 were admitted to the 
study. All subjects had undergone proctocolectomy 3-27 years earlier because of 
ulcerative colitis (n=8) or polyposis coli (n=1), and all had an intact ileum. The 
subjects gave their informed consent before the start of the study. 
Supplements 
We prepared French-press coffee by pouring 1 L of boiling water onto 65 g of 
coarsely ground coffee (Roodmerk, Douwe Egberts, The Netherlands) in a glass jug 
(Kaffee Primo, BMF, Germany). The brew was thoroughly stirred and allowed to 
stand for 3 min. The plastic strainer was pushed down and the liquid was decanted. 
For each subject we weighed 150, 300 or 450 ml_ of the coffee brew into a thermos 
flask so as to provide 1, 2 or 3 cups of coffee, respectively. We stored another 100 
mL of each individual brew at -20 °C for diterpene analysis. 
Study design 
We used a multiple cross-over design (figure 2) in which all volunteers first 
followed a run-in period of seven days. On day seven, subjects received a 
standardised breakfast without coffee. Subsequently, they were randomly assigned 
to three treatment sequences, each consisting of three treatment days separated by 
one wash-out week. Treatment on day 14, 21 and 28 consisted of consumption of the 
same standardised breakfast as on day seven, plus either one, two or three cups of 
French-press coffee. Subjects also swallowed 20 radio-opaque barium-salt-
impregnated plastic ringlets with an outer diameter of 3 mm (TD Medical, Eindhoven, 
The Netherlands). These markers provide a validated method for the assessment of 
solid food recovery in ileostomists (12). Subjects were restricted from eating and 
drinking for 2 h after breakfast, except for having tea without milk or sugar, or water. 
On all treatment days, subjects swallowed with their meals three capsules containing 
80 mg of para-aminobenzoic acid each per day to check for complete urine 
collection. Para-aminobenzoic acid is completely absorbed and excreted with urine in 
humans (13). The participants were allowed to drink only filtered or instant coffee 
throughout the study, as these coffee types contain negligible amounts of cafestol 
and kahweol (1). Participants recorded any deviation from their usual diet and 
physical activity pattern in a diary, as well as any signs of illness, and medication 
used. 
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Figure 2. Design of the study. Nine healthy ileostomy volunteers followed a run-in period of seven 
days and were randomly assigned to three treatment sequences, each consisting of three treatment 
days. On day seven, a standardised breakfast was provided and subsequently ileostomy effluent was 
collected every 2 h for about 14 h. On day 14, 21 and 28, a standardised breakfast with a single dose 
of either one, two or three cups of French-press coffee was provided, ileostomy effluent was collected 
every 2 h for about 14 h, and urine was collected for 24 h. On the day when three cups of French-
press coffee had to be consumed, subjects collected urine every 2 h. In the night preceding every 
experimental day, a pre-treatment sample of ileostomy effluent and urine was obtained. 
Collection of samples 
On days 7, 14, 21 and 28, subjects collected ileostomy effluent throughout the day 
for 14.1 ±0.7 (mean±SD) h after coffee consumption. They also collected a pre-
treatment sample during the night preceding each experimental day. Subjects 
changed ileostomy bags every 2.1 ±0.2 h and immediately stored them on dry ice. We 
counted the number of radio-opaque ringlets in the ileostomy samples by X-raying 
within the next two days. We separated the plastic ileostomy bags from their contents 
using liquid nitrogen, and freeze-dried the contents. We checked sample weights 
once or twice a day during the process of freeze-drying, and immediately removed 
them from the freeze-dryer when stable weight was reached. Samples were ground 
to pass a 0.5 mm sieve and stored at -20°C until analysis. 
Subjects collected urine for 24 h after each coffee dose. Control urine samples 
were collected during the night preceding each treatment day. On the day on which 3 
cups of French-press coffee were provided, subjects collected 24-h urine in timed 
portions every 2.0±0.1 h during daytime and in 1 portion during the night. Urine was 
voided into 0.5 L nalgene bottles containing 5 ml_ toluene (Janssen Chimica) each, 
and immediately put on dry ice. The following morning we warmed the urines to 
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37°C, mixed, and took aliquots for cafestol, kahweol and para-aminobenzoic acid 
analysis. Aliquots were stored at -20°C. 
In vitro incubation of diterpenes with gastro-intestinal fluids 
We evaluated the stability of cafestol and kahweol palmitate in gastric and 
duodenal juice in vitro in order to assess possible losses of diterpenes during gastro-
intestinal transit. Gastric and duodenal juice were obtained from 2 healthy fasting 
volunteers at the department of Gastro-enterology, Nijmegen University Hospital, The 
Netherlands, and stored at -20°C. We incubated 6, 12 and 18 mL of French-press 
coffee with 4 mL of gastric juice and 1 mL of water each for 0, 20 and 60 min at 37°C. 
This mimicked stomach contents after the administration of 1, 2 and 3 cups of coffee 
(14;15). To assess if a low pH affects the recovery of diterpenes during stomach 
passage, we made five solutions of HCI in demineralised water with pH values of 
0.72, 1.43, 2.19, 3.56, and 4.05. One volume of each solution was added to 3 
volumes of French-press coffee. This yielded incubation samples with pH values of 
1.56, 3.89, 4.63, 4.81 and 4.92, respectively. Distilled water was used for the control 
incubation. Samples were incubated at 37°C for 20 and 60 min, frozen immediately, 
and stored at -20°C. In addition, we incubated 6, 12 and 18 mL of French-press 
coffee with 2 mL of duodenal juice (Department of Gastro-enterology, Nijmegen 
University Hospital, The Netherlands) plus 1 mL of water each for 0,1 and 4 h: 1 and 
4 h reflect the estimated mean and maximum transit time in the human small 
intestine, respectively (16;17). All samples were frozen with liquid nitrogen 
immediately after the incubation, and stored at -20°C. 
We also assessed stability of cafestol and kahweol palmitate during collection of 
the effluent in the ileostomy bag and during freeze-drying. To that end, we incubated 
70 mg of a mixture of cafestol plus kahweol palmitate dissolved in 0.5 mL ethanol 
with 50 g of fresh ileostomy effluent obtained from 8 subjects for 2 and 0 h, 
respectively, at 30°C. The samples were shaken every 15 min during incubation. 
Samples were immediately frozen in liquid nitrogen, freeze-dried and stored at -20°C. 
To asses the stability of cafestol and kahweol during freeze-drying in detail, we 
dissolved 40.7 mg aliquots of cafestol plus kahweol palmitate in 0.4 mL ethanol plus 
9.6 mL distilled water, and freeze-dried such samples for various time periods. 
Analytical methods 
Cafestol and kahweol in ileostomy effluent. We analysed samples with and without 
pre-treatment with an enzyme preparation having B-glucuronidase activity (100,000 
units/mL) and sulphatase activity (5,000 units/mL) (Sigma, G7017). The pre-
treatment consisted of incubating 300 mg of thawed ileostomy effluent with 200 uL of 
(3-glucuronidase and 2 mL of 0.4 mol/L phosphate buffer (pH 5) in a water bath of 
37°C for 1 h. Subsequently, we prepared samples for diterpene analysis as 
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described by Urgert et al (1). Briefly, we added 2 mL of 5 mol/L methanolic KOH to 
both pre-treated and not pre-treated samples and saponified the samples for 1 h at 
80°C. After cooling the samples, lipids were extracted by adding 5 mL of di-isopropyl 
ether (Merck, Darmstadt, Germany, no. 867), shaking for 10 min at 250 
oscillations/min and centrifuging for 10 min at 3000 rpm. We collected the ether 
phase, and re-extracted the water phase twice with diisopropyl ether. The combined 
ether phases were washed twice with 3 mL of distilled water. The ether phase was 
evaporated with nitrogen, and the remnant was dissolved in 1 mL of methanol (Lab 
Scan, no. C2517). Of each sample, 10 p i was injected into an HPLC system 
(Shodex degas, SP8875 autosample, SP8800 ternary HPLC pump, Spectra Focus 
detector, Thermo Separation Products) equipped with two serially connected reverse 
phase Spherisorb ODS columns, 100 x 3 mm each (Chrompack, Middelburg, The 
Netherlands). The elution solvent, which consisted of 62.5% (v/v) methanol and 
37.5% filtered distilled water, was administered at a flow rate of 0.4 mL/min. 
Detection was at both 220 and 290 nm, which reflects the optimal absorption of 
cafestol and kahweol, respectively. The coefficients of variation for a control sample 
of faeces containing a known amount of cafestol and kahweol were 10.6% within and 
7.0% between runs over a 6 month's period for cafestol, and 8.2% and 7.1%, 
respectively, for kahweol. 
Cafestol and kahweol in urine. The urine samples were thawed and centrifuged. 
Two mL of the supernatant was incubated with 1 mL of 0.4 mol/L phosphate buffer 
(pH 5) and 200 nL of 6-glucuronidase at 37°C for 1 h, adsorbed to a 500 mg reverse 
phase C18 column (Varian products, USA), washed twice with 1 mL of distilled water, 
and extracted with 3 mL of methanol. The extract was evaporated and the remnant 
dissolved in 250 (J.L methanol/H20, 62.5/37.5 v/v. Twenty (j,L was injected into the 
HPLC system, equipped with two serially connected reverse phase ChromSpher C8 
columns, 100 x 3 mm each (Chrompack). Other conditions were as described for 
ileostomy effluent. Two urine samples from a previous experiment (18), one with a 
low and one with a high cafestol and kahweol content, showed a coefficient of 
variation for cafestol of 14.4% and 4.6%, respectively, within, and 15.8% and 9.8%, 
respectively, between runs over a 6 month's period. For kahweol, coefficients of 
variation were 25.8% and 11.1%, respectively, within, and 12.8% and 16.1%, 
respectively, between runs. 
Cafestol and kahweol in coffee and gastro-intestinal fluids. We analysed coffee 
and fluid samples as described by Urgert et al. (1). The coefficients of variation for a 
control pool of boiled coffee were 2.5% within and 9.5% between runs over a 6 
month's period for cafestol and 2.3% and 7.2% for kahweol, respectively. 
Para-aminobenzoic acid in urine. We determined para-aminobenzoic acid 
spectrophotometrically with fluorescamine (Roche, 071088) as described previously 
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(19). Addition of 200 u.g of para-aminobenzoic acid to 1 ml_ of urine yielded a 
recovery of 96% (n=2). 
Results 
Collection of ileostomy effluent and urine 
Of the twenty radio-opaque ringlets swallowed, 93±13% (mean±SD) were 
recovered in the ileostomy bags. One subject refrained from swallowing the ringlets 
on the third treatment day after consultation with the researchers, because during the 
first two experimental days she had excreted less than 50% of the 20 ingested radio-
opaque ringlets. Data analyses were performed with and without this subject's results 
on diterpene excretion in ileostomy effluent. 
Recovery of para-aminobenzoic acid in 24-h urine was 85±16% (mean±SD). Four 
persons showed on ten separate occasions a urinary recovery of para-aminobenzoic 
acid of less than 85%. Data analyses were performed with and without the results of 
these ten occasions. 
Stability of cafestol and kahweol during incubation with gastro-intestinal fluids 
During in vitro incubation in gastric juice, recoveries of cafestol decreased by 
25±10% (mean±SD, n=6 incubations) after 20 min and 23±9% after 60 min. 
Recovery of kahweol decreased by 22±9% (n=6 incubations) after 20 min and 
25±6% after 60 min. Outcomes were irrespective of the dose of French-press coffee, 
and therefore data were pooled per incubation time period. Recoveries of cafestol 
and kahweol after incubation with HCI dilutions with pH values of 0.7, 1.4, 2.2, 3.6, 
and 4.1, were 89±9% (mean±SD, n=8 incubations), 112±3%, 113±6%, 116±5% and 
113±6%, respectively. We pooled data per pH because outcomes were irrespective 
of the incubation time. The diterpenes were stable during incubation in duodenal 
juice for 1 and 4 h. Incubation of cafestol and kahweol with ileostomy effluent for 2 h 
plus subsequent freeze-drying yielded a recovery of 56±5% (n=6 incubations) for 
both cafestol and kahweol. 
Stability of cafestol and kahweol during freeze-drying 
Recovery of cafestol and kahweol palmitate in ileostomy effluent during freeze-
drying was 74±5% (n=4 incubations) for cafestol and 68±4% (n=4 incubations) for 
kahweol. Cafestol plus kahweol palmitate dissolved in ethanol and distilled water 
were stable during freeze-drying until all water had disappeared, i.e. after 8 h. Then 
recovery decreased to 60% for cafestol and 37% for kahweol during an additional 22 
h of freeze-drying. Therefore, loss of cafestol and kahweol during freeze-drying 
appears to occur mainly after samples lost their water content. 
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Figure 3. Algorithm to calculate absorption of cafestol and kahweol. Data were calculated as described 
in the Results section. Losses during incubation with gastric juice, during storage in ileostomy effluent 
and during freeze-drying were estimated with data obtained from in vitro experiments. 
Calculations 
We used an algorithm to correct the absorption of cafestol and kahweol in the 
small intestine for losses in gastric juice, in ileostomy effluent and during freeze-
drying (figure 3). We calculated the individual absorption of cafestol and kahweol 
expressed as the percentage of the amount consumed as follows: 
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Cafestol absorption as percentage of the amount consumed (%) = 
(((X-0.24X)-((Y/0.74)/0.83))/X)*100 
Kahweol absorption as percentage of amount consumed (%) = 
(((X-0.23X)-((Y/0.68)/0.88))/X)*100 
where X was the amount consumed with the French-press coffee, and Y the amount 
detected in freeze-dried ileostomy effluent. Absorption of cafestol and kahweol 
expressed as percentage of the amount entering the duodenum was calculated as 
follows: 
Cafestol absorption as percentage of the amount entering the duodenum (%) = 
(((X-0.24X)-((Y/0.74)/0.83))/(X-0.24X))*100 
Kahweol absorption as percentage of the amount entering the duodenum (%) = 
(((X-0.23X)-((Y/0.68)/0.88))/(X-0.23X))*100 
Cafestol and kahweol excretions in urine were corrected for estimated losses in the 
stomach (cafestol 24% and kahweol 23%). 
Absorption and excretion of coffee diterpenes 
No cafestol or kahweol was found in ileostomy effluent collected on the pre-
experimental control day (figure 2, day 7), when no French-press coffee was 
provided. However, significant amounts of the coffee diterpenes were found in pre-
treatment samples of two subjects collected in the night preceding an experimental 
day. Data analyses were therefore performed with and without the results obtained 
from the subsequent two experimental days. The reason for the presence of the 
coffee diterpenes in the pre-treatment samples is not clear. Both subjects declared 
not to have consumed any coffee other than filtered coffee during the experiment. It 
might be that cafestol and kahweol are not unique for coffee beans. So far, however, 
these coffee diterpenes have not been found in other foods. 
Only free cafestol and kahweol was detected in ileostomy effluent; addition of I3-
glucuronidase with sulphatase activity did not result in a higher diterpene content 
(data not shown). Mean (±SD) absorption of cafestol and kahweol expressed as 
percentage of the ingested amount and as percentage of the amount entering the 
duodenum, after correction for the estimated losses, is illustrated in table 1. 
No free cafestol or kahweol was found in urine. Urinary excretion of glucuronidated 
or sulphated cafestol and kahweol occurred mostly within 8 h after consumption of 
the French-press coffee, indicating that collection was complete. There was a 
considerable variation in the subjects' excretion rates, possibly due to interindividual 
differences in phase II enzyme activities (figure 4). Mean (±SD) excretion of cafestol 
and kahweol in 24-h urine is illustrated in table 1. 
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Figure 4. Cumulative excretion of cafestol and kahweol in urine of 9 subjects after consumption of 3 
cups of French-press coffee. The heavy line represents the mean. 
Discussion 
We found that about 70% of the ingested cafestol and kahweol from French-press 
coffee was absorbed in ileostomy volunteers. Most of the other 30% was degraded in 
gastric fluid before it could reach the duodenum. Absorption of the cafestol and 
kahweol that reached the duodenum was about 90%. Only a small part was 
subsequently excreted as a conjugate of glucuronic acid or sulphate in urine. 
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Validity of the ileostomy model 
We studied the excretion of cafestol and kahweol in subjects whose colon had 
been resected. The advantage of the ileostomy model is the absence of microbial 
degradation in the colon. When 2-h portions of ileostomy effluent during daytime and 
one portion during the night were subjected to immediate freezing on dry ice, virtually 
no microbial degradation on protein, fat, and dietary fibre in the ileostomy bags was 
found (20;21), and degradation of bile acids and neutral sterols was absent or 
minimal (22;23). In our samples, however, we did find a mean degradation of 18% of 
cafestol and of 12% of kahweol 2 h after addition to freshly collected ileostomy 
effluent. A part of the cafestol and kahweol reaching the ileostomy bag might be 
degraded by microflora excreted from the terminal ileum. Substantial bacterial 
colonisation of the terminal ileum in ileostomists has been reported (24-26). If indeed 
bacteria are responsible for the degradation of cafestol and kahweol in ileostomy 
effluent, use of the ileostomy model does not appear to exclude effects of microflora 
on all substances present in the ileostomy bag. 
We could not avoid freeze-drying, since this is the only way to obtain 
homogeneous samples for the analysis. Losses of cafestol and kahweol during 
freeze-drying might be due to the formation and sublimation of cafestolene and 
kahweolene: these contain an additional double bond between C15 and C16 
compared to the original diterpenes (27). Loss of cafestol and kahweol became high 
after the water had disappeared. However, we immediately removed samples from 
the freeze-dryer upon reaching stable weight. Therefore, losses of cafestol and 
kahweol have been minimised. 
Gastro-intestinal transit of coffee diterpenes 
We found a considerable loss of cafestol and kahweol present in French-press 
coffee during in vitro incubation with representative amounts of gastric juice. 
Although the number of in vitro incubations was few, the results were consistent. 
Therefore, these in vitro data strongly indicate that at least a part of the consumed 
diterpenes is transformed into other compounds during gastric passage. As the 
recovery of cafestol and kahweol with gastric juice were equally affected, the double 
bond between C1 and C2 in the kahweol molecule does not appear to play an 
important role. Recovery of cafestol and kahweol was slightly smaller after incubation 
with a solution with a pH value of 0.72, compared to solutions with pH values ranging 
from 1.43-4.05. Therefore, high concentrations of HCI might in part be responsible for 
the transformation of diterpenes during incubation with gastric juice. However, the 
24% decrease in recovery of coffee diterpenes during incubation with gastric juice 
cannot be fully explained by low pH. 
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Absorption of coffee diterpenes 
An algorithm based on losses determined in vitro enabled us to estimate the 
absorption of cafestol and kahweol expressed as percentage of the amount 
consumed and expressed as percentage of the amount entering the duodenum. Both 
calculated mean absorptions might show variation between the 9 subjects because 
of interindividual differences in the proportion of diterpenes in ileostomy effluent 
compared to the amount consumed. Our algorithm, however, does not consider the 
variation of the mean losses determined in vitro in the calculation of individual 
absorption values. Therefore, the real variation in mean absorption will be 
underestimated. We calculated that the standard deviation of the amount of cafestol 
and kahweol leaving the stomach (in the formula presented as X-0.24X for cafestol 
and X-0.23X for kahweol) has 10 times more influence on the total variation of an 
individual absorption value than the standard deviation of the amount entering the 
colon (in the formula presented as (Y/0.74)/0.83 for cafestol and (Y/0.68)/0.88 for 
kahweol). These standard deviations taken together lead to a coefficient of variation 
of 16% for the absorption of cafestol expressed as percentage of the ingested 
amount and of 13% for the absorption of kahweol as percentage of the ingested 
amount. This indicates that two thirds of the absorption values expressed as 
percentage of the ingested amount will lie in a range of 52-84% for cafestol and 56-
81% for kahweol. 
As estimated losses were about equal for both cafestol and kahweol, excretion in 
ileostomy effluent is expected to be similar. However, kahweol excretion was 
somewhat lower than that of cafestol. This is in agreement with earlier observations 
in faeces (28). Kahweol might be absorbed more efficiently than cafestol. Also, the 
double bond of the kahweol molecule might be hydrogenated by bacteria present in 
the terminal ileum. 
Collection of ileostomy effluent during the daytime appeared to cover all cafestol 
and kahweol excreted. Pilot experiments revealed that no cafestol and kahweol was 
present in ileostomy effluent sampled 12 h after the consumption of French-press 
coffee (data not shown). 
Urinary excretion of coffee diterpenes 
We measured excretion of diterpenes as conjugate of glucuronic acid and 
sulphate in urine, because glucuronidation and sulphation are the major pathways of 
xenobiotic biotransformation in mammalian species (29). We hypothesised that at 
least a part of the ingested cafestol and kahweol will not undergo phase I 
metabolisation, as they already possess hydroxyl groups. Conjugation of this part 
with a hydrophilic moiety appears to be necessary for excretion of the fat-soluble 
coffee diterpenes by the kidney. Indeed, no free cafestol and kahweol was present in 
urine from subjects receiving diterpene-rich supplements in previous experiments 
30 
Absorption and excretion of coffee diterpenes 
(28). However, since only about 1% of the ingested amount was excreted as 
conjugate of glucuronic acid or sulphate in urine, the major part of the absorbed 
diterpenes must be metabolised more extensively than just glucuronidation or 
sulphation of the cafestol and kahweol molecule. 
There are some indications that phase I metabolites might undergo conjugation 
with glutathione; kahweol palmitate and to a lesser extent cafestol palmitate induced 
glutathione S-transferases activity in the mucosa of the small intestine and in the liver 
of mice (30). The furan moiety of cafestol and kahweol appears vital for this effect 
(31). 
We did not find glucuronidated or sulphated conjugates of cafestol and kahweol in 
ileostomy effluent. This can implicate that cafestol and kahweol conjugates of 
glucuronic acid or sulphate are small enough to be excreted into urine instead of into 
bile, or that the ileostomy effluent matrix inhibits 13-glucuronidase. Also, the fact that 
we found only a small percentage of the absorbed cafestol and kahweol as 
conjugates of glucuronic acid or sulphate in urine suggests that glucuronidation or 
sulphation of cafestol and kahweol are minor processes. Since we did not measure 
other metabolites of cafestol and kahweol than conjugates of glucuronic acid and 
sulphate, the presence of other metabolites might overestimate the absorption 
percentages as calculated with the algorithm. 
In conclusion, about 90% of the cafestol and kahweol that enters the small 
intestine is absorbed there. Absorption of these coffee diterpenes expressed as 
percentage of the amount consumed is about 70%. This indicates that of each 10 mg 
of cafestol in French-press coffee consumed, 7 mg of cafestol is absorbed in the 
small intestine and available for raising serum cholesterol by about 0.13 mmol/L in 
man. The question remains which part of the ingested diterpenes eventually raises 
serum lipids, since we did not study the fate of cafestol and kahweol in the pre-
systemic circulation. Only 0.8 mg will enter the colon; the amounts available for the 
presumed anticarcinogenic effects of coffee diterpenes (10) are thus very small. 
Moreover, only a very small amount of the cafestol and kahweol that enters the 
circulation is subsequently excreted as conjugate of glucuronic acid or sulphate in 
urine. Therefore, the major part of the ingested cafestol and kahweol must be 
metabolised different from just glucuronidation or sulphation of the cafestol and 
kahweol molecule. 
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Validity of animal models for the cholesterol-raising 
effects of coffee diterpenes in humans 
Baukje de Roos, Janet K. Sawyer, Martijn B. Katan and Lawrence L. Rudel. 
Proceedings of the Nutrition Society, in press. 
Abstract 
Cafestol and kahweol - coffee lipids present in unfiltered coffee brews - potently 
increase low density lipoprotein (LDL) cholesterol concentration in humans. We 
searched for an animal species in which cafestol similarly increases LDL cholesterol. 
Such an animal model could subsequently be used as a model to study the 
mechanism of action of cafestol and kahweol. Cafestol and kahweol increased serum 
lipids in African green monkeys, Cebus and Rhesus monkeys, hamsters, rats, and 
gerbils differently than in humans. In African green monkeys, the rise in total 
cholesterol was less significant than in man. In addition, the increase in total 
cholesterol was predominantly due to a rise in HDL cholesterol rather than LDL 
cholesterol. Therefore, the rise in plasma lipids might illustrate the mechanism in 
these monkeys rather than the mechanism in humans. In other animal species, 
cafestol and kahweol did not raise cholesterol consistently. The variability in effects 
on serum lipids could not be explained by the mode of administration or dose of 
diterpenes, nor by the amount of cholesterol in the diet. In conclusion, we did not find 
an animal model in which cafestol and kahweol elevate plasma lipoproteins to the 
same extent as in man. For the time being, therefore, studies on the mechanism of 
action should preferably be done in humans. 
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Introduction 
Unfiltered coffee brews markedly increase serum lipids in humans. The 
compounds responsible for this effect are cafestol and kahweol, which are present in 
coffee beans (1 ;2). The mechanism by which coffee diterpenes influence lipoprotein 
metabolism is largely unknown. An animal model with a response to cafestol and 
kahweol similar to that in man would allow mechanistic studies that otherwise could 
not be done in man. We here review the use of animal models for understanding the 
action of cafestol and kahweol in humans. 
Effect of the coffee diterpenes on serum lipids in humans 
The cholesterol raising potential of unfiltered coffee depends mainly on its content 
of cafestol (3). Unfiltered coffee brews such as Scandinavian boiled coffee, cafetiere 
(French-press) coffee, and Turkish coffee contain about 3-6 mg of cafestol per cup 
(4;5). Filtered coffee does not contain cafestol, because coffee diterpenes are 
insoluble in water and do not pass through a paper filter (6). In short term studies 
each 10 mg of cafestol ingested raised serum cholesterol an average of 0.13 mmol/L 
and serum triglycerides an average of 0.08 mmol/L after four weeks. Effects are 
linear up to 100 mg of cafestol ingested per day (7). In a long term study the cafestol 
content of five cups of cafetiere coffee ingested per day caused a persistent rise in 
serum total cholesterol of 11-17% and a rise in LDL cholesterol of 9-14% after 24 
weeks (8). Hence, about 80% of the rise in total cholesterol was accounted for by 
LDL cholesterol, and the rest was due to a rise in VLDL cholesterol. Cafetiere coffee 
did not affect HDL cholesterol levels, although coffee diterpenes did slightly decrease 
HDL cholesterol concentration in some previous studies (2;3;7;9). Serum triglycerides 
rose markedly (26%) after two to four weeks of intake of cafetiere coffee. However, 
the rise in serum triglycerides subsided with chronic intake of coffee diterpenes (8). 
To study how cafestol affects serum lipoproteins in humans, we would like to use 
an animal model with a lipoprotein metabolism similar to humans. One criterion would 
be that the animal's response to dietary cholesterol is similar to that in man. Rats, 
mice, dogs and squirrel monkeys respond to dietary cholesterol by down-regulation 
of cholesterol synthesis and by up-regulation of bile acid production (i.e. cholesterol 
7oc-hydroxylase) in the liver. As a consequence, plasma lipoprotein concentrations do 
not increase (10). In contrast, bile acid production is not affected when humans 
increase their cholesterol intake, while serum LDL and HDL cholesterol 
concentrations will increase. Hamsters, guinea pigs, cynomolgus monkeys, Cebus 
monkeys, Rhesus monkeys, African green monkeys, baboons, and pigs have, like 
humans, a low rate of cholesterol synthesis in the liver (11). In addition, these 
species do not increase bile acid synthesis when fed cholesterol. Instead, liver 
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cholesterol content increases, LDL receptor activity is down-regulated and LDL 
cholesterol concentration in the plasma increases (10). Therefore, the response to 
dietary cholesterol in these animal species is similar to man. 
Male African green monkeys show many similarities with humans in the effects of 
dietary cholesterol and fatty acids on plasma lipoproteins and cholesterol metabolism 
(12-14). Therefore, we studied whether the African green monkey is also a good 
model for the effect of cafestol and kahweol on lipoprotein metabolism in man. In 
addition, we here review whether we can use Rhesus or Cebus monkeys, hamsters, 
rats, gerbils, or mice as a model to study the mechanism of action of the coffee 
diterpenes. 
Effect of coffee diterpenes in African green monkeys and man 
We fed eight male African green monkeys with a mean age of 15.9 years and a 
mean weight of 4.4 kg a "Western type" diet with a caloric distribution of 17% protein, 
35% fat (15% saturated fat) and 48% carbohydrate. 96 mg Crystalline cholesterol per 
MJ of diet was added in order to produce total plasma cholesterol concentrations of 
5-8 mmol/L, i.e. the range seen in humans. This diet was either supplemented with 
placebo oil consisting of sunflower oil and palm oil (3:2 wt/wt) or with coffee oil. Both 
oils had a similar content of fatty acids (15). The diets provided 0.26 g of these oils 
per kg body weight per day; as a result the coffee oil diet provided 8 mg cafestol and 
7 mg kahweol per kg body weight per day. 
During a run-in period of six weeks, all monkeys consumed the placebo oil diet. 
During the first treatment periods of seven weeks, four animals were given the 
placebo oil diet, while the other four received the coffee oil diet. The two groups had 
similar initial cholesterol concentrations (mean 6.41 (SD 2.76) vs. mean 6.37 (SD 
2.07)). This period was followed by a wash-out period of five weeks, where only the 
placebo diet was provided. Then followed a second treatment period of seven weeks, 
in which the placebo oil diet and the coffee oil diet were switched. Blood samples 
were taken in week 5 of the run-in period, in week 5, 6 and 7 of both treatment 
periods, and in week 5 of the wash-out period. In plasma we determined total 
cholesterol, LDL cholesterol, HDL cholesterol and triglycerides as described by Carr 
efa/(16). 
Food intake and body weight did not change during the experimental period. 
Coffee oil raised total plasma cholesterol by 14%, LDL cholesterol by 8%, and HDL 
cholesterol levels by 23% (table 1). About 32% of the rise in cholesterol was 
accounted for by LDL cholesterol and 57% by HDL cholesterol. We assume that the 
remaining 11% was accounted for by VLDL+IDL cholesterol. Coffee oil increased 
plasma triglycerides by 35% compared to placebo oil. 
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Plasma levels of alanine aminotransferase did not differ between the placebo and 
the coffee oil periods (table 1), which indicates that liver cell integrity was not 
disturbed. In two previous animal studies, coffee diterpenes also did not affect 
plasma alanine aminotransferase (15; 17). 
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Chapter 3 
The response in plasma cholesterol was higher in the four animals that consumed 
the coffee oil diet in the second treatment period than in the four animals that 
consumed the coffee oil in the first treatment period: 26% versus 2% for total 
cholesterol; 21% versus -5% for LDL cholesterol; and 59% versus -12% for HDL 
cholesterol, respectively (figure 1). The reason for this could be the relatively short 
run-in period of 6 weeks on the high fat, high cholesterol placebo oil diet. In monkeys, 
a steady state in proportions of fatty acids in the liver pools, in the distribution of 
unesterified and esterified cholesterol in liver, in LDL receptor activity in the liver, in 
LDL cholesterol production, and in plasma LDL cholesterol are reached in 
approximately three months of feeding a high cholesterol, high fat diet (18). The four 
monkeys that consumed the coffee oil diet in the second treatment period had 
consumed the placebo oil diet for 18 weeks before they received the coffee oil diet. 
Therefore, the data of these latter four monkeys may give a better indication of the 
lipid-elevating effect of the coffee oil. 
The monkeys received per day on average 35 mg of cafestol and 31 mg of 
kahweol at an energy intake of 2.21 MJ. The daily intake would have been 160 mg 
cafestol and 140 mg kahweol if the monkeys were fed the same amount of energy as 
humans, i.e. 10 MJ per day. This amount of diterpenes is present in 25 cups of 
unfiltered coffee (7), and it would raise serum cholesterol by on average 2.05 mmol/L 
or 40% and serum triglycerides by on average 1.26 mmol/L or 120% in humans (7). 
The response of plasma cholesterol to coffee oil in African green monkeys was in the 
same direction, but significantly weaker than in man. Also, unlike humans, in the 
monkeys the rise in cholesterol was primarily due to increases in HDL cholesterol 
rather than in LDL cholesterol. Therefore, the action of cafestol and kahweol on 
lipoprotein metabolism may illustrate that the mechanism in this monkey species is 
different than the mechanism in humans. These data show that an animal species 
which is a good model to study the mechanisms of dietary cholesterol and fatty acids 
on lipoprotein metabolism may not necessarily be a good model to study the 
mechanism of cafestol and kahweol. 
Coffee diterpenes fail to show consistent results in other animal species 
In contrast to the present findings in African green monkeys, coffee oil did not 
affect plasma cholesterol and triglycerides in Cebus and Rhesus monkeys (15). 
These monkeys consumed a daily amount of cafestol corresponding to that present 
in 12-13 cups of boiled coffee per 10 MJ of diet (figure 2). This dose is half that given 
to the African green monkeys, which might explain why the Cebus and Rhesus 
monkeys did not respond. In addition, the Cebus and Rhesus monkeys received a 
lower dose of dietary cholesterol (figure 2), which also might help to explain the lack 
of effect on serum lipids, because in various animal experiments the influence of fed 
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components on serum cholesterol appeared greater against a dietary background 
rich in cholesterol (19). 
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Figure 2. Comparison of the effect of cafestol in man with that in various animal species. Bars indicate 
the mean ± 95% confidence intervals. Treatment periods varied from two to twenty weeks. Cafestol 
intake was recalculated to the amount of cups of coffee that would need to be consumed per 10 MJ 
per day, assuming that each 150 mL-cup of unfiltered coffee contains 6.2 mg of cafestol. The mean 
preparations of known diterpene content were given. 
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In male Syrian hamsters, coffee diterpenes had no consistent effect on serum 
lipids (figure 2). Boiled coffee elevated plasma cholesterol and triglycerides in one 
study with Syrian hamsters by Sanders & Sandaradura (20), but our attempt to 
replicate this result was unsuccessful (17). In another study by Ratnayake et al. 
(1995) coffee oil, a diterpene rich fraction from coffee beans and purified diterpenes 
also did not affect serum lipids in hamsters (21), even though the animals received 
the same amount of dietary cholesterol and a much higher dose of cafestol than the 
hamsters in the study of Sanders & Sandaradura (20). Paradoxically, serum 
cholesterol was significantly increased when Ratnayake et al (1995) repeated this 
experiment with a much lower dose of cafestol, dietary cholesterol, and saturated 
fatty acids (21). 
Rats also failed to show a consistent response of serum lipids upon cafestol 
treatment (figure 2). Boiled coffee (22) and coffee oil (Terpstra, unpublished 
observations) significantly increased serum cholesterol both on a low and high 
cholesterol diet. However, in two other studies using Wistar rats, serum lipids were 
not affected by unfiltered coffee (17;23) although one of these studies used a 
background diet which was relatively high in cholesterol (17). 
Two studies presented data on the effects of coffee in male gerbils (figure 2). In 
our hands, freeze-dried boiled coffee did not affect serum cholesterol in gerbils (24). 
However, the process of freeze-drying may remove or modify the cafestol in the 
diets. In a second study we fed gerbils coffee oil from the same source and lot as we 
used in our human studies. Here, coffee oil significantly elevated plasma cholesterol 
compared to placebo oil (Terpstra, unpublished observations). 
We have also studied the effects of cafestol and kahweol on serum lipoproteins in 
hyperlipidaemic LDL receptor knock-out mice and apolipoprotein E*3-Leiden mice 
(chapter 4). A dose equivalent to 8 or 40 cups of unfiltered coffee per 10 MJ per day 
raised serum cholesterol to the same extent in these mouse species as in man. The 
coffee diterpenes also raised serum cholesterol in the wild type (C57BI/6) mice 
(chapter 4). However, the rise in total cholesterol was predominantly due to a rise in 
VLDL and IDL cholesterol and not to a rise in LDL cholesterol. 
The form in which diterpenes were given - as pure compounds, as coffee oil or as 
unfiltered coffee - does not appear to explain the inconsistent effects on serum lipids 
in animals. Also the dose of coffee diterpenes does not explain the variability of the 
effects. Both high and low doses of diterpenes caused a significant rise in serum 
lipids in some animals (figure 3). In addition, a dietary background rich in cholesterol 
is neither necessary nor sufficient to produce a rise in serum cholesterol in animals 
(figure 3). As yet, there is no animal species in which cafestol and kahweol uniformly 
raised serum cholesterol. Therefore, criteria such as study design and chance 
fluctuations might explain why cafestol raised serum cholesterol in some animal 
species, whereas other species did not respond to coffee diterpenes. 
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cholesterol (expressed in mg cholesterol per 10 MJ per day) used in these studies. 
Conclusion 
The effect of cafestol and kahweol on lipoprotein metabolism in monkeys, 
hamsters, rats and gerbils differs from that in humans. In African green monkeys, 
coffee diterpenes appeared to raise HDL as much as LDL, although no statistical 
significance for either lipoprotein was found. The small group size and time on diet 
appeared to limit the significance of the outcome. In the other animal species, 
cafestol and kahweol did not raise serum cholesterol consistently and to the same 
extent as in man. We will gain little knowledge by extrapolating these effects of 
cafestol and kahweol on plasma lipoproteins in animals to humans unless the animal 
model has first shown to respond to the intervention as humans do. For the time 
being, studies on the mechanism of action should preferably be done in humans. 
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Cafestol, the cholesterol-raising factor in boiled 
coffee, increases serum cholesterol levels in 
apolipoprotein E*3-Leiden transgenic mice by 
suppression of bile acid synthesis 
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Abstract 
Cafestol, a diterpene present in unfiltered coffee brews, potently increases serum 
cholesterol levels in humans. So far, no suitable animal model has been found to 
study the biochemical background of this effect. We determined the effect of cafestol 
on serum cholesterol and triglycerides in different strains of mice and studied 
subsequently the mechanism of action in apolipoprotein E*3-Leiden transgenic mice. 
Apolipoprotein (apo) E*3-Leiden, heterozygous LDL receptor knock-out (LDLR+/-) 
or wild type C57BI/6 (WT) mice were fed a high (0.05% w/w) or low (0.01% w/w) 
cafestol diet or a placebo diet for eight weeks. Standardised to energy intake, these 
amounts equal 40, 8 or 0 cups of unfiltered coffee per 10 MJ per day in humans. In 
apoE*3-Leiden mice, serum cholesterol was increased by 33% (3.46 mmol/L; 95%CI 
[1.62;5.30]) on the low and by 61% (6.35 mmol/L; 95%CI [4.47;8.22]) on the high 
cafestol diet. In LDLR+/- and WT mice, the increases were 20% (0.85 mmol/L; 
95%CI [-0.25;1.94]) and 24% (0.62 mmol/L; 95%CI [0.34;0.90]), respectively, on the 
low cafestol diet, and 55% (2.37 mmol/L; 95%CI [0.73;4.01]) and 46% (1.21 mmol/L; 
95%CI [0.92;1.50]), respectively, on the high cafestol diet. The increase in total 
cholesterol was mainly due to a rise in VLDL and IDL cholesterol in all three mouse 
strains. 
To investigate the mechanism of the cholesterol-raising effect, apoE*3-Leiden 
mice were fed a high cafestol or a placebo diet for three weeks. Cafestol suppressed 
enzyme activity and mRNA levels of cholesterol 7oc-hydroxylase by 57% and 58% 
(both p<0.05), respectively. mRNA levels of enzymes involved in the alternative 
pathway of bile acid synthesis, i.e. sterol 27-hydroxylase and oxysterol 7a-
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hydroxylase, were reduced by 32% (p<0.05) and 48% (p<0.005), respectively. The 
total amount of bile acids secreted in faeces was decreased by 41%. Cafestol did not 
affect hepatic free and esterified cholesterol, but it decreased LDLR mRNA levels by 
37% (p<0.05). VLDL particles contained a three times higher amount of cholesteryl 
esters, indicative for the secretion of a I3VLDL-Iike particle. This was confirmed by a 
decreased VLDL triglyceride production, as measured by the increase in triglycerides 
after Triton injection, in mice treated with cafestol (35.1+13.8 u.mol/h/kg) compared to 
placebo treatment (63.1±17.5 |xmol/h/kg). This was a result of a reduction in hepatic 
triglyceride content by 52% (p<0.05). 
In conclusion, cafestol increases serum cholesterol levels in apoE*3-Leiden 
transgenic mice by suppression of the major regulatory enzymes in the bile acid 
synthesis pathways, leading to decreased LDLR mRNA levels and increased 
secretion of cholesteryl esters by the liver. In analogy, we suggest that suppression 
of bile acid synthesis may provide an explanation for the cholesterol-raising effect of 
cafestol in humans. 
Introduction 
Unfiltered coffee brews markedly increase serum cholesterol levels in humans. 
The responsible compounds for this effect are cafestol and kahweol, two diterpenes 
that are present in coffee beans (1). From our experiments, cafestol appeared to be 
by far the most potent compound (2). We estimated that each 10 mg of cafestol 
ingested per day raises serum cholesterol levels by 0.13 mmol/L (3). In humans, 
about 80% of the rise in total cholesterol is accounted for by low density lipoprotein 
(LDL) cholesterol, and the rest is due to a rise in very low density lipoprotein (VLDL) 
cholesterol (4). 
The mechanism by which coffee diterpenes influence lipid metabolism is largely 
unknown. Recently, we reported that cafestol suppressed bile acid synthesis in 
cultured rat hepatocytes by down-regulation of cholesterol 7cc-hydroxylase and sterol 
27-hydroxylase (5). Suppression of bile acid synthesis will lead to an increased pool 
of regulatory cholesterol, resulting in a decreased expression of the hepatic LDL-
receptor. This may provide an explanation for the cholesterol-raising effect of cafestol 
in humans (5). The availability of an animal model to study this hypothesis in vivo 
would be of great value, since it may help us to validate our in vitro experiments and 
eventually to discover the metabolic control points of cafestol. However, in previous 
studies, various animal models like hamsters (6-8), rats (6;9), gerbils (8), Cebus, 
Rhesus and African green monkeys (10) did not respond to cafestol and kahweol as 
humans do, regardless of the dosage, the mode of administration or the duration of 
the treatment. Differences in the absorption and/or metabolism of coffee diterpenes, 
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or in their effects on lipoprotein metabolism, might underlie the negative results in a 
range of animal species. 
We here studied the effects of cafestol and kahweol on serum lipoproteins in 
apolipoprotein E*3-Leiden (apoE*3-Leiden) transgenic mice, in heterozygous LDL 
receptor deficient (LDLR+/-) mice, and in wild type (WT) C57BI/6 mice. We chose to 
use transgenic mice over-expressing human apoE*3-Leiden, since these mice are 
highly susceptible to diet-induced hyperlipoproteinemia, primarily due to a partial 
defect in hepatic uptake of remnant lipoproteins (11 ;12). Since it was anticipated from 
our studies in cultured rat hepatocytes that cafestol would have an indirect effect on 
the expression of the LDL-receptor (5), experiments were also performed with 
LDLR+/- mice. Lipoprotein profiles from LDLR+/- mice are more similar to humans 
than those from WT mice, which transport most of their cholesterol in the HDL 
lipoprotein fraction (13). The cholesterol-raising effect of cafestol appeared to be 
most pronounced in apoE*3-Leiden transgenic mice, allowing us to investigate the 
mechanism of the cholesterol-raising effect of cafestol in this mouse strain. 
Animals and methods 
Animals, housing and diet 
Twenty-four female apoE*3-Leiden mice (mean age 19 ± 5 weeks), 24 female 
LDLR+/- mice (mean age 32 ± 2 weeks) and 24 female WT C57BI/6 mice (mean age 
19 ± 5 weeks) were held under standard conditions in Macrolon type III cages 
housing 4 animals. All cages were placed under filtertops to prevent infection. They 
were maintained on 12-h dark and 12-h light cycles and were allowed free access to 
food and water. Body weight of the mice and the consumption of diet and water were 
recorded weekly during the whole experimental period. Mice were fed a common 
challenge diet enriched with saturated fat and cholesterol (18.2 MJ/kg) containing per 
100 g: cacao butter 15 g, corn oil 1 g, cholesterol 0.25 g, sucrose 40.5 g, corn starch 
10 g, cellulose 5.9 g, minerals 2.6 g, and vitamins 8.2 g (Hope Farms, Woerden, The 
Netherlands). This diet was supplemented with either 0.05% (w/w) cafestol and 
0.025% (w/w) kahweol (high cafestol diet), 0.01% (w/w) cafestol and 0.005% (w/w) 
kahweol (low cafestol diet), or no cafestol and kahweol (placebo diet). Standardised 
to daily energy intake, these amounts are comparable with a daily amount of 40, 8 or 
0 cups of unfiltered coffee, respectively, per 10 MJ (the average daily energy intake 
in humans). Diets were stored at -20°C until use and food was renewed twice a 
week. Institutional guidelines for animal care were observed in all experiments. 
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Experimental design 
Per mice strain, animals were randomly divided into three experimental groups of 
eight mice each, matched by age and serum cholesterol. During a run-in period of 
four weeks, all mice received the placebo diet. During the treatment period of eight 
weeks, the groups consumed either the high or the low cafestol diet, or the placebo 
diet. About 100 \iL of blood was taken at week 0, 2, 4 and 8 of the treatment period 
by orbital puncture after an overnight fasting period. Faeces were sampled during 
three days in week 3 and in week 6 of the experimental period. They were stored at -
20°C until analysis of bile acids. After eight weeks of treatment, mice were 
anaesthetised with ether, bled and cervically dislocated. 
Measurement of serum lipids and lipoproteins 
In serum, total cholesterol and triglycerides (without free glycerol) were measured 
enzymatically (CHOD-PAP method, Boehringer Mannheim, #236691, and GPO-
trinder, Sigma, #337-B, respectively). Alanine aminotransferase was measured 
enzymatically (GPT, Boehringer Mannheim, #745138) after pooling the serum of four 
mice in one cage. Subsequently, serum lipoproteins were separated by 
ultracentrifugation. For this, 25 \iL of serum per mouse was pooled per treatment 
group. 200 jaL of pooled serum was layered with 1 mL of potassium bromide 
(p=1.21), 2.58 mL of sodium chloride (p=1.063), and 8 mL of distilled water in a poly-
allomer tube (Beckman instruments, Mijdrecht, The Netherlands). The tubes were 
centrifuged for 18 h at 40.000 rpm at 4°C in a Beckman SW41 rotor. Then, the 
volume was fractionated in 47 fractions using a peristaltic pump (LKB Micro Perspex) 
and a fractionating apparatus (LKB Redifrac). In each fraction, cholesterol was 
measured enzymatically as described above, and the density was checked with a 
densitometer (Mettler DMA 45, Graz, Austria). 
Enzyme activity of cholesterol 7a-hydroxylase and sterol 27-hydroxylase 
In livers from mice which had been on a high cafestol or placebo diet for three 
weeks, enzyme activities of cholesterol 7oc-hydroxylase in microsomes and sterol 27-
hydroxylase in mitochondria were determined essentially according to Chiang (14). 
This method measures the mass conversion of cholesterol into 7a- and 27-
hydroxycholesterol. Briefly, 1 mg of either microsomal or mitochondrial protein was 
incubated in 1 mL of buffer containing 0.1 mol/L potassium phosphate pH 7.2, 50 
mmol/L NaF, 5 mmol/L DTT, 1 mmol/L EDTA, 20% (w/v) glycerol and 0.015 % (w/w) 
3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulfonate) (CHAPS). Twenty uL 
of 1 mg cholesterol in 45% (w/v) hydroxypropyl-p-cyclodextrin was added and the 
mixture was incubated under agitation for 10 min at 37 °C. Then 200 uL of a 
regenerating system containing 10 mmol/L sodium isocitrate, 10 mmol/L MgCI2, 1 
mM NADPH and 0.15 U isocitrate-dehydrogenase was added at 37°C. After 20 min 
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of incubation, 60 uL of a stop solution containing 20% (w/v) sodium cholate and 1 ug 
20a-hydroxycholesterol, which served as a recovery standard, were added. After 
addition of 100 uL buffer containing 0.1% (w/v) cholesteroloxidase (Calbiochem, 
USA, #228250), 10 mmol/L potassium phosphate pH 7.4, 1 mM DTT and 20% 
glycerol (w/v), steroid products were oxidised at 37 °C for 45 min. The reaction was 
stopped by the addition of 2 mL ethanol. Cholesterol metabolites from this reaction 
mixture were extracted in petroleum ether and the ether layer was evaporated under 
a stream of nitrogen. Residues were re-suspended in a mixture of 60% acetonitril, 
30% methanol and 10% chloroform (v/v). This mixture was analysed using a C-18 
reverse phase HPLC on a Tosohaas TSK gel-ODS 80TM column equilibrated with 
50% acetonitril and 50% (v/v) methanol at a flow rate of 0.8 mL/min. The amount of 
the products formed was determined by monitoring the absorbance at 240 nm. Peaks 
were integrated using Data Control software (Cecil Instruments, UK). 
RNA isolation, blotting and hybridisation procedures 
Isolation of total RNA, and subsequent electrophoresis, northern-blotting and 
hybridisation techniques were performed as described previously (5;15). The 
following DNA fragments were used as probes in hybridisation experiments: a 1.6 kb 
PCR-synthesised fragment of rat cholesterol 7a-hydroxylase cDNA, spanning the 
entire coding region; a 1.6 kb H/ndlll/Xbal fragment of rat sterol 27-hydroxylase 
cDNA, a 1.2 kb H/ndlll fragment of murine oxysterol 7oc-hydroxylase cDNA (16), and 
a 2.2 kb EcoRI fragment of rat LDL-receptor cDNA. As controls, a 1.2 kb Psti 
fragment of rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA and a 
3.8 mDa EcoRI fragment of the human 18S ribosomal DNA were used (17). The 
GAPDH mRNA or 18S rRNA was used as an internal standard to correct for 
differences in the amount of total RNA applied onto the gel or filter. mRNA levels 
were quantitated using a Phosphor-imager BAS-reader (Fuji Fujix BAS 1000) and the 
computer programs BAS-reader version 2.8 and TINA version 2.09. 
Determination of total bile acid concentration and bile acid composition in 
faeces 
Dried faeces (25 mg) were treated with 1 mL alkaline methanol (methanol : 1 
mol/L NaOH 3:1 (v/v)) for 2 h at 80°C in screw capped tubes. Then 9 mL of distilled 
water was added and the tubes were mixed and centrifuged. Total bile acid 
concentration was determined enzymatically/fluorimetrically on 100 uL of the 
supernatant applying 3oc-hydroxysteroid dehydrogenase (18; 19). The total residual 
supernatant was subsequently applied to a prepared Sep-Pak C18 solid phase 
extraction cartridge for determination of individual bile acid concentrations (19). After 
a clean up by wash procedures, bile acids were eluted with 75% methanol (20). 
Coprostanol was used as an internal standard. The eluate was evaporated to 
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dryness and the bile acids were methylated with acetyl chloride/methanol 1:20 (v/v) 
for 30 min at 60°C. The samples were then evaporated to dryness and silylated with 
100 (il bis-trimethylsilyl-trifluoroacetamide (BSTFA)/pyridine/trimethylchlorosilane 
(TMCS) 5:4:1 (v/v) at room temperature for at least 1 h. The methyl-TMS derivatives 
were separated on a 25 m x 0.25 mm capillary OV-1701 GC column (CP Sil 19CB, 
Chrompack International, Middelburg, The Netherlands) (20) in a HP6890 gas 
chromatograph (Hewlett Packard, Palo Alto, Ca, USA) equipped with a flame 
ionisation detector (FID). The injector was kept at 280°C, the FID detector at 300°C. 
Helium was used as carrier gas at a flow rate of 0.8 mL/min. The column temperature 
was programmed from 240 to 280°C at a rate of 10°C/min. Bile acid derivatives were 
introduced by split-injection (split ratio 20:1). Quantitation was based on the area 
ratio of the individual bile acid to the internal standard. 
Determination of neutral sterol composition and concentration in faeces 
Dried faeces (25 mg) were treated with 1 ml_ alkaline methanol as described for 
bile acid measurement to liberate neutral sterols from faeces material. Prior to this 
treatment, 5oc-cholestane was added as internal standard. After treatment, the tubes 
were cooled to room temperature and the neutral sterols were extracted three times 
with 3 mL petroleum ether. The combined petroleum ether layers were evaporated to 
dryness and the neutral sterols silylated to TMS derivatives using the same protocol 
as described for bile acids. Analysis of the TMS derivatives was performed by GC 
applying the same column and analytical conditions as described for the methyl TMS 
derivatives of bile acids. Quantitation was based on the area ratio of the individual 
neutral sterol to the internal standard 5a-cholestane. 
Measurement of liver lipids 
Liver samples from mice which had been on a high cafestol or placebo diet for 
three weeks were homogenised and samples were taken for measurement of protein 
content. Two ug of cholesterol acetate was added per sample as an internal 
standard. Then, lipids were extracted from the homogenate according to Bligh & Dyer 
(21). The neutral lipids were separated by high performance thin layer 
chromatography on silica-gel-60 pre-coated plates as described previously (5;22). 
Quantitation of the lipid amounts was performed by scanning the plates with a 
Hewlett Packard Scanjet 4c and by integration of the density areas with the computer 
program Tina version 2.09. 
In vivo hepatic VLDL production in apoE*3-Leiden mice 
Mice which had been on a high cafestol or placebo diet for three weeks were 
fasted for 4 h (from 8.00-12.00 a.m.) and then injected with Triton WR 1339 (500 
mg/kg body weight). Triton virtually completely inhibits serum VLDL clearance (23). 
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Subsequently, serum triglycerides were determined prior to injection (t=0 min) and 
30, 60, 90, 120 and 180 min after Triton injection. The hepatic VLDL production rate 
was calculated from the slope of the curve and expressed as umol/h/kg body weight. 
Serum collected 180 min after Triton injection was pooled per treatment group and 
VLDL was subsequently isolated by ultracentrifugation in triplicate. Triglycerides, total 
and free cholesterol, and phospholipids were measured enzymatically as described 
previously (24). Cholesteryl esters were subsequently calculated as the difference 
between total and free cholesterol. 
Statistical analyses 
We calculated the change in serum lipids per mouse by subtracting values at the 
start of the experimental period from values obtained during the experimental period. 
After checking for normality, differences in changes between treatment groups and 
the control group were tested using the one-tailed unpaired Student's t-test. Other 
data were analysed statistically using a two-tailed Student's unpaired t-test with the 
level of significance selected to be p<0.05. Values are expressed as means ± SD. 
Results 
Food, body weight and alanine aminotransferase 
In all mouse strains, the average change in body weight was significantly higher in 
mice fed the placebo diet compared to mice fed the high cafestol diet (p<0.05)\ 
average daily food intake was significantly higher in mice fed the placebo diet 
compared to mice fed the low and high cafestol diet {p<0.05). Concentrations of the 
liver enzyme alanine aminotransferase (ALT) did not significantly increase during 
consumption of cafestol in all mouse strains (table 1). 
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F/gure 2. Effect of a high cafestol (0.05% w/w) diet on cholesterol profiles in apolipoprotein E'3-Leiden 
mice (upper part), LDLR+A mice (middle part) and WT (C57BI/6) mice (lower part). The white marks 
indicate the cholesterol profile from pooled serum of 8 mice at the start of the experimental period 
(t=0). The black marks indicate the cholesterol profile from pooled serum of 8 mice after 8 weeks of 
treatment with the high cafestol diet. Serum was fractionated as described in Animals and Methods. 
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Cafestol increases serum lipid and lipoprotein levels 
Cafestol raised serum cholesterol in all three mouse strains after eight weeks of 
dietary intervention (figure 1). In apoE*3-Leiden transgenic mice, serum cholesterol 
was raised by 33% (3.46 mmol/L; 95%CI [1.62;5.30]) in the low cafestol diet group 
and by 61% (6.35 mmol/L; 95%CI [4.47;8.22]) in the high cafestol diet group. !n 
LDLR+/- mice, serum cholesterol was raised by 20% (0.85 mmol/L; 95%CI [-0.25; 
1.94]) in the low cafestol diet group and by 55% (2.37 mmol/L; 95%CI [0.73;4.01]) in 
the high cafestol diet group. In WT mice, serum cholesterol was raised by 24% (0.62 
mmol/L; 95%CI [0.34;0.90]) in the low cafestol diet group and by 46% (1.21 mmol/L; 
95%CI [0.92;1.50]) in the high cafestol diet group. In all mouse strains, the rise in 
serum cholesterol was predominantly due to a rise in VLDL and IDL cholesterol 
(figure 2). Serum triglycerides were increased after two weeks in apoE*3-Leiden 
transgenic and WT mice and remained significantly higher in the apoE*3-Leiden 
transgenic mice during cafestol treatment compared to placebo treatment (figure 1). 
Since the effects on serum cholesterol were most pronounced in the apoE*3-Leiden 
transgenic mice, we proceeded with this animal model to study the mechanism of the 
cholesterol-raising effects of cafestol. 
Cafestol decreases hepatic enzymes in bile acid synthesis and faecal excretion 
of bile acids 
To validate the effects of cafestol on bile acid synthesis obtained in cultured rat 
hepatocytes (5), we determined the effect of a high cafestol diet during three weeks 
on enzymes involved in bile acid synthesis and on faecal bile acid excretion in 
apoE*3-Leiden transgenic mice. Cafestol decreased the cholesterol 7a-hydroxylase 
activity and mRNA levels by 57% and 58%, respectively (both p<0.05) (table 2). 
Cafestol also decreased sterol 27-hydroxylase mRNA levels by 32% [p<0.05), while 
the enzyme activity was paradoxically increased by 40% (p<0.05) (table 2). It is well-
known, however, that mitochondria may contain oxysterol 7<x-hydroxylase (25), as 
found in pigs (26) and in humans (27), converting 27-hydroxycholesterol into 7a,27-
dihydroxycholesterol (25-27). Thus, it is possible that the apparent increase in sterol 
27-hydroxylase activity can be attributed to accumulation of its product, 27-
hydroxycholesterol, caused by a blockade in the subsequent metabolic conversion. 
Therefore, we measured mRNA levels of oxysterol 7oc-hydroxylase. The expression 
of this enzyme was decreased by 58% (p<0.005), giving an explanation for the 
apparent increase in sterol 27-hydroxylase activity (table 2). 
57 
Chapter 4 
Table 2. Effect of cafestol on hepatic mRNA and activity levels in apo E*3-Leiden mice 
Placebo diet High cafestol diet 
Cholesterol 7a-hydroxylase 
Sterol 27-hydroxylase 
Oxysterol 7a-hydroxylase 
LDL receptor 
activity 
100 ± 5 
100 ±10 
N.D. 
N.D. 
mRNA activity 
(% of placebo) 
100 ±41 
100 ±12 
100 ±21 
100 ±26 
43 ± 1 * 
140 ±5 
N.D. 
N.D. 
mRNA 
42 ±7* 
68 ±17 
41 ±16 
63 ±14 
ApoE*3-Leiden mice were treated with a high cafestol diet or a placebo diet for 3 weeks. Hepatic 
enzyme activities and mRNA levels of mice treated with a high cafestol (0.05% w/w) or placebo diet 
were determined after a 4 hour fasting period from 8 till 12 a.m. The amount of mRNA was corrected 
for differences in total RNA applied to the gel, using 18 S ribosomal RNA as an internal standard. 
Absolute activities of cholesterol 7a-hydroxylase and sterol 27-hydroxylase from apoE*3-Leiden mice 
treated the placebo diet were 1.83 nmol/h/mg protein and 1.76 nmol/h/mg protein, respectively. Data 
shown are means ± SD (n=4 per group). A significant difference between placebo and cafestol diet is 
indicated by an asterisk" (p<0.05), (p<0.005). N.D.: not determined. 
Since down-regulation of enzymes involved in bile acid synthesis has 
consequences for the overall process of bile acid production, the amount of total and 
individual bile acids was measured in faeces. Cafestol decreased the total amount of 
bile acids excreted in the faeces with 41% as compared to the placebo diet (table 3). 
In addition, cafestol changed the relative amount of the various bile acids in the 
faeces showing an increase in the ratio between bile acids formed only via the 
neutral or 7a-hydroxylated pathway (deoxycholate and cholate) and those formed via 
the neutral as well as the acidic or 27-hydroxylated pathway (remaining bile acids) 
(28;29) (table 3). Furthermore, the amount of faecal neutral sterols excreted in the 
cafestol treated group was slightly lower as compared to the placebo group indicating 
that inhibition of bile acid synthesis does not lead to an increased secretion of free 
cholesterol into bile (table 3). The effect on the excretion and composition of faecal 
bile acids and neutral sterols was similar after three and six weeks on the high 
cafestol or placebo diet. 
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Effect of cafestol on VLDL production and hepatic lipid metabolism in apoE*3-
Leiden transgenic mice 
In order to investigate the effects of a decreased bile acid synthesis on hepatic 
lipid metabolism, we determined the amount of hepatic lipids of apoE*3-Leiden 
transgenic mice treated with a high cafestol or placebo diet for three weeks. Cafestol 
decreased the hepatic triglyceride content by 52% (p<0.05), but it did not alter the 
liver free and esterified cholesterol levels (table 4). Although the hepatic content of 
free cholesterol in apoE*3-Leiden mice was apparently not affected by cafestol, the 
regulatory pool of cholesterol was increased as indicated by a decreased expression 
of the LDL receptor (-37%, p<0.05) (table 2). 
Table 4. Effect of cafestol on hepatic cholesterol and triglyceride content in apo E*3-Leiden mice 
Treatment 
Placebo 
Cafestol 
Mice were treated with a high cafestol diet or a placebo diet for three weeks. In liver homogenates, 
free cholesterol, cholesteryl esters and triglycerides were determined using a h.p.t.l.c. method (see 
Animals and methods) after a 4 hour fasting period. Data are means ± SD (n=4). Values between 
parenthesis represent the percentage of the value obtained in animals treated with the placebo diet. A 
significant difference between control and treated mice is indicated by an asterisk' (p<0.05). 
Table 5. Effect of cafestol on VLDL composition in apo E*3-Leiden mice. 
Free cholesterol 
15.5 ±1.5 
14.4 ±1.3 
(93%) 
Cholesteryl ester 
(pg/mg protein) 
38.3 ± 7.7 
32.8 ±11.9 
(85%) 
Triglycerides 
86.3 ±10.6 
41.1 ±8.7 
(48%) 
Treatment 
Placebo 
Cafestol 
Triglycerides 
52.0 ± 3.0 
28.9 ±10.1 
Free cholesterol Cholesteryl ester 
% of total lipid (by weight) 
7.8 ±0.8 17.5 ±2.9 
6.6 ±1.1 49.2 ±12.7 
Phospholipids 
22.7 ±5.0 
15.3 ±1.7 
VLDL was isolated by ultracentrifugation from pooled serum of eight fasted apo E*3-Leiden transgenic 
mice treated with a high cafestol or a placebo diet for three weeks. The serum was collected 180 min 
after Triton injection. Triglycerides, total cholesterol, free cholesterol and phospholipids were 
measured enzymatically and the amount of cholesteryl ester was calculated (see Animals and 
methods). Data are means ± SD of three individual VLDL samples of each group. A significant 
difference between control and cafestol treated mice is indicated by an asterisk (p<0.05). 
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Since the excess hepatic cholesterol was not excreted into the bile, it might have 
been secreted by the liver in VLDL particles. Therefore, we measured nascent VLDL 
production in apolipoprotein E*3-Leiden transgenic mice after three weeks on a high 
cafestol or placebo diet. The relative amount of cholesteryl esters in the VLDL 
particles upon cafestol treatment was almost three times higher compared to placebo 
treatment (p<0.05), while the relative amount of triglycerides in the particles was 
decreased by about 50% (table 5). This was reflected in a two times lower VLDL 
triglyceride production rate (35.1 ±13.8 umol/h/kg after the high cafestol diet versus 
63.1 ±17.5 umol/h/kg after the placebo diet) (figure 3). 
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Figure 3. Effect of cafestol on the VLDL triglyceride production rate in apoE*3-Leiden mice. Triton WR 
1339 (500 mg/kg body weight) was injected into placebo (white marks) and cafestol (0.05% w/w) 
(black marks) treated apoE*3-Leiden mice (n=8 fasted mice per group). Serum triglyceride levels were 
determined at 30, 60, 90, 120 and 180 min and corrected for the triglyceride level at the time of 
injection (t=0 min). The values shown are means ± SD. 
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Discussion 
In this study, cafestol increased serum cholesterol levels in apoE*3-Leiden, 
heterozygous LDL receptor deficient, and in wild type (C57BI/6) mice, mainly in the 
VLDL and IDL fraction. In apoE*3-Leiden transgenic mice, cafestol decreased bile 
acid synthesis reflected by a reduction in the total amount of faecal bile acids by 
down-regulation of expression of enzymes involved in the neutral as well as in the 
alternative bile acid synthetic pathway. The decrease in bile acid synthesis resulted 
in a decline in LDL receptor mRNA levels and an increased secretion of VLDL 
cholesteryl ester. 
So far, no suitable animal model has been found to study the mechanism of action 
of cafestol, since various animal models did not respond to this coffee diterpene as 
humans do (6-10). ApoE*3-Leiden transgenic mice are the first animals showing a 
similar increase in serum cholesterol due to cafestol as observed in humans, making 
this species a good model to investigate the biochemical background of the 
cholesterol-raising effect of cafestol in humans. It should be noted that the increase 
in serum cholesterol in humans is mainly present in LDL, whereas in the mice the rise 
is predominantly found in the VLDL-IDL range. 
Previously, we reported that cafestol suppressed bile acid synthesis by down-
regulation of cholesterol 7a-hydroxylase and sterol 27-hydroxylase expression in rat 
hepatocytes (5). This is now confirmed in vivo in apolipoprotein E*3-Leiden 
transgenic mice. In this study we also showed that the total bile acid mass in faeces 
of the cafestol-treated group was decreased. Cafestol predominantly affected 
cholesterol 7oc-hydroxylase and oxysterol 7oc-hydroxylase, but the effects on sterol 
27-hydroxylase also contributed to the decreased faecal bile acid mass since cafestol 
changed the faecal bile acid composition. The ratio between bile acids formed only 
via the neutral or 7a-hydroxylated pathway (deoxycholate and cholate) and those 
formed via the neutral as well as the acidic or 27-hydroxylated pathway (remaining 
bile acids) (28;29) increased. This indicates inhibition of the acidic pathway in bile 
acid synthesis next to an inhibitory effect on the neutral pathway. 
Theoretically, a suppressed bile acid synthesis would increase the pool of free 
cholesterol in the liver cell. We did not find an effect on hepatic free cholesterol 
levels, but different metabolic pathways might have converted the free cholesterol 
into cholesteryl esters or removed it from the liver as such and/or via VLDL particles 
to maintain the hepatic cholesterol homeostasis. Since we did not find an increase in 
faecal excretion of neutral sterols or a hepatic accumulation of cholesteryl esters, it 
appears plausible that the cholesterol which becomes available due to inhibition of 
bile acid synthesis is directly removed from the liver via VLDL particles (see below). 
In addition, high amounts of free cholesterol in the cell membranes (30) may 
overshadow subtle changes in free cholesterol caused by inhibition of bile acid 
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synthesis. We found a substantial decrease in LDLR mRNA, which is a sensitive 
measure to detect changes in the regulatory pool of free cholesterol. Subtle 
increases in intracellular cholesterol prevent processing of sterol regulatory element 
binding protein (SREBP), resulting in a down-regulation of LDL-receptor gene 
transcription (31). A similar decrease in LDLR mRNA levels has been shown in vitro 
in cultured rat hepatocytes (5) and in HepG2 cells (32). In contrast, divergent data 
were reported in other cell types (33;34), possibly because of the different metabolic 
functions of these cells. Our results plead in favour of the hypothesis that the 
cholesterol-raising effect of cafestol can be explained at least in part by a reduced 
expression of the LDL receptor. 
The rise in serum cholesterol upon cafestol treatment may also partly be explained 
by an increased secretion of cholesteryl esters in VLDL. The relative amount of 
cholesteryl esters in the VLDL particles upon cafestol treatment was significantly 
higher compared to placebo treatment. Concomitantly, the relative amount of 
triglycerides in the particles decreased. This reduction was to the same extent as the 
decline in the VLDL-triglyceride production rate. This suggests that not the number of 
particles but the composition is changed, resulting in the production of a GVLDL-like 
particle. The decrease in the VLDL-triglyceride production rate and the reduced 
triglyceride content of the liver suggests an impaired triglyceride synthesis. Whether 
this is due to a direct or indirect effect of cafestol on activity or expression of enzymes 
involved in triglyceride synthesis awaits further investigation. 
In conclusion, we found that cafestol inhibits bile acid synthesis by down-
regulation of both the neutral and the acidic pathway leading to a decrease in the 
expression of the LDL receptor and an elevated secretion of cholesteryl esters in 
VLDL. Suppression of bile acid synthesis may provide an explanation for the 
cholesterol-raising effects of unfiltered coffee in humans. 
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Consumption of cafetiere coffee raises cholesteryl 
ester transfer protein activity levels before LDL 
cholesterol in normolipidaemic subjects 
Baukje de Roos and Arie van Tol, Rob Urgert, Leo M. Scheek, Teus van Gent, Rien 
Buytenhek, Hans M.G. Princen, and Martijn B. Katan. Submitted. 
Abstract 
Cafestol and kahweol, diterpene lipids present in unfiltered coffee, raise serum 
LDL cholesterol concentrations in humans. We investigated whether the serum lipid 
transfer proteins cholesteryl ester transfer protein (CETP) and phospholipid transfer 
protein (PLTP) might be involved in the mechanism of action of unfiltered coffee. In 
addition, we determined the long-term effects of cafetiere coffee consumption on the 
activity level of serum lipid transfer proteins and lecithin: cholesterol acyltransferase 
(LCAT). Forty-six healthy normolipidaemic subjects consumed 0.9 L of either 
cafetiere or filtered coffee for 24 weeks. Relative to baseline, cafetiere coffee 
significantly increased average CETP activity by 12% after 2 weeks, by 18% after 12 
weeks, and by 9% after 24 weeks. LDL rose by 2% after 2 weeks, by 12% after 12 
weeks, and by 7% at 24 weeks. The increase in CETP clearly preceded the increase 
in LDL cholesterol. PLTP activity was significantly increased by 10% after 12 and 24 
weeks. LCAT activity was significantly decreased by 6% after 12 weeks and by 7% 
after 24 weeks. We conclude that the increased CETP activity during consumption of 
cafetiere coffee may contribute to the rise in LDL cholesterol. 
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Introduction 
Long-term consumption of unfiltered coffee potently raises serum low density 
lipoprotein (LDL) cholesterol in humans (1). The lipid soluble diterpenes cafestol and 
kahweol - present in coffee beans (2) - are responsible for this effect (3). These 
diterpenes are the most potent cholesterol-raising substances from the diet that are 
known. Therefore, the action of cafestol and kahweol offers an interesting model to 
study the effect of dietary substances on cholesterol metabolism in humans. 
The mechanism of action of cafestol and kahweol is poorly understood. In vitro 
studies show contradictory results in various cell lines. Cafestol decreased LDL 
receptor activity in human fibroblasts (4), in HepG2-cells (5) and in primary rat 
hepatocytes (6). However, in CaCo-2 cells, cafestol enhanced LDL cholesterol 
uptake and degradation (7). We earlier found that in humans, consumption of 
diterpenes is associated with increased serum activity levels of the lipid transfer 
proteins cholesteryl ester transfer protein (CETP) and phospholipid transfer protein 
(PLTP) and with decreased activity levels of lecithin: cholesterol acyltransferase 
(LCAT) (8). CETP catalyses the transfer of cholesteryl esters - synthesised by LCAT 
- from HDL to the apolipoprotein B-containing lipoproteins LDL and VLDL (9). PLTP 
can affect the net mass transfer of phospholipids between lipoproteins (10) and it 
also converts small-sized HDL (HDL3) both into larger (HDL2-sized) and smaller 
(preB-migrating) HDL particles (11-13). Both CETP and PLTP appear to play a major 
role in determining the concentration and size of HDL particles in plasma (10;14). In 
our earlier study (8) it remained unclear whether the elevated serum CETP and 
PLTP activity levels in subjects consuming diterpenes were a cause or a 
consequence of the raised LDL cholesterol concentrations. 
In the present experiment we studied whether serum lipid transfer proteins might 
play a role in the mechanism of action of cafestol and kahweol in humans. For this 
purpose, we compared the initial changes occurring in lipid transfer protein activity 
levels with the initial changes in LDL and HDL cholesterol levels during cafetiere 
coffee consumption. Filtered coffee was used as a control. We reasoned that an 
increase in a lipid transfer protein activity prior to an increase in LDL cholesterol 
could indicate a role of this protein in the mechanism of action. In addition, we 
determined the long-term effects of consumption of cafetiere coffee on lipid transfer 
protein activity levels and LCAT. 
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Subjects and Methods 
Subjects 
Approval for the experiments was obtained from the Human Ethics Committee of 
the Division of Human Nutrition & Epidemiology, Wageningen Agricultural University. 
Forty-six subjects gave their written informed consent and participated in the study. 
These subjects had a mean age of 30 years (range 19-69) and a BMI of 23±3 
(mean±SD) kg/m2. Sixteen of these subjects were smokers. Alcohol consumption 
was limited to less than three beverages per day per subject. 
Design 
During a run-in period of four weeks subjects consumed 0.9 L of filtered coffee per 
day. Subsequently, they were stratified by age and serum alanine aminotransferase 
and then randomly allocated to consume 0.9 L of either filtered coffee (n=24 
subjects; 12 male and 12 female) or cafetiere coffee (n=22 subjects; 11 male and 11 
female) per day for 24 weeks. Subjects brewed their coffee at home. Filtered coffee 
was prepared by scooping 33 g of finely ground coffee into a paper filter and pouring 
1.1 L of boiling water onto the grounds. Boiled coffee was prepared by scooping 39 g 
of coarse grounds into a cafetiere (Kaffee Primo, BMF, Germany) and pouring 1.2 L 
of boiling water onto the grounds. Subjects stirred the brew for 10 seconds, allowed it 
to stand for 2-5 minutes, pushed down the plunger to separate the grounds from the 
brew, and then decanted the brew. This amount of cafetiere coffee provided about 
38 mg cafestol and about 33 mg kahweol per day. Filtered coffee provided less than 
1 mg of either diterpene a day. Both coffee brews contained similar amounts of 
caffeine. 
Blood sampling and assays 
Fasting venous blood samples were taken after 0, 2, 12 and 24 weeks of 
intervention and after 12 weeks of follow up. Serum was obtained by centrifugation 
and stored at -80°C. Total serum triglycerides, LDL cholesterol and HDL cholesterol 
were assayed as described (1). Serum CETP activity levels were assayed in 
duplicate after removal of endogenous VLDL + LDL (15) using excess exogenous 
substrates. The isotope assay measures the transfer of [1-14C-oleate]cholesteryl 
ester from labelled LDL to an excess of unlabelled pooled normal HDL, while LCAT 
is inhibited with dithiobis-2-nitrobenzoic acid (16). CETP activity was calculated as 
the bi-directional transfer between labelled LDL and HDL. The CETP activity levels 
obtained by this method correlate well with CETP mass (17). Serum PLTP activity 
levels were assayed in duplicate in a phospholipid vesicles-HDL system, as 
described (15). In short, small serum samples of 0.5-1.0 \i\ were incubated with 
[^phosphatidylcholine labelled liposomes and an excess of pooled normal HDL, 
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followed by precipitation of the liposomes with a mixture of NaCI, MgCI2 and heparin 
(final concentrations of 230 mmol/L, 32 mmol/L and 200 U/mL, respectively). The 
measured PLTP activity is not influenced by the phospholipid transfer promoting 
properties of CETP (15). Serum LCAT activity levels were measured in duplicate, 
using excess exogenous substrate containing [3H]cholesterol as described (18). The 
measured LCAT activity levels vary linearly with the amount of serum added to the 
incubation mixture. The measured activity is indicative for the serum LCAT 
concentration (19). Serum CETP, PLTP and LCAT activity levels were related to 
human pool serum and expressed in arbitrary units (AU, which corresponds to the 
percentages of the activities present in the serum pool). All subjects were analysed 
using one batch of substrates. The within assay coefficients of variation of CETP, 
PLTP and LCAT were 2.7%, 3.5% and 4.5%, respectively. 
Statistics 
Responses were calculated by subtracting baseline values from values obtained 
during treatment. All variables were normally distributed. Differences in responses 
between the cafetiere and filtered-coffee group were tested against zero with 
unpaired t-tests. 
Results 
CETP activity was significantly elevated already after two weeks of cafetiere 
coffee consumption compared to filtered coffee consumption (table 1). At this point, 
CETP had already reached 68% of its maximal increase that was reached after 12 
weeks of intervention. The increase in LDL cholesterol only became significant after 
12 weeks (figure 1). At two weeks, LDL cholesterol had only reached 18% of its 
maximal increase that was reached after 12 weeks of intervention. A maximum 
increase of 18% over baseline value in CETP activity and 10% over baseline value in 
PLTP activity was reached after 12 weeks (figure 1). Both CETP and PLTP activity 
dropped just below baseline after consumption of cafetiere coffee had ceased. LCAT 
activity was significantly decreased by about 6% after 12 and 24 weeks of cafetiere 
coffee consumption and returned to baseline after cessation of treatment (table 1). 
As reported previously (1), triglycerides and thus presumably VLDL peaked already 
at the first measuring point. No significant changes were detected in HDL cholesterol 
(figure 1). 
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F/gure 7. /Wean changes from baseline values in serum activity levels of CETP, PLTP and LCATand of 
serum concentrations of LDL and HDL cholesterol and triglycerides in 22 subjects drinking 0.9 L of 
cafetiere coffee per day for 24 weeks. For each time point, mean changes from baseline in 24 subjects 
drinking filtered coffee were subtracted from those in the subjects drinking cafetiere coffee. 
Discussion 
We found that consumption of cafetiere coffee increased CETP activity before it 
increased LDL cholesterol concentrations in a group of healthy normolipidaemic 
subjects. During consumption of cafetiere coffee, CETP activity levels had already 
reached 68% of their maximum levels at the first measurement point, two weeks 
after subjects had started to drink unfiltered coffee rich in cafestol. At that point in 
time, LDL levels had reached only 18% of their maximum level (figure 1). PLTP 
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activity levels were significant increased and LCAT activity levels were significantly 
decreased only after 12 and 24 weeks of intervention. 
The present findings extend our earlier data obtained with purified coffee 
diterpenes (8). In our previous experiments, it remained unclear whether elevated 
activity levels of CETP and PLTP due to cafestol or kahweol consumption were a 
cause or a consequence of elevated serum LDL cholesterol levels (8). Earlier human 
studies on the effects of a high fat, high cholesterol diet on serum CETP also do not 
provide clear evidence for a causal relationship, e.g. in favour of a mechanism with 
increased serum CETP activity levels causing increased serum LDL cholesterol 
levels (20-22). Data from animal models are not conclusive either. Some studies in 
transgenic mice suggest that increased CETP levels may be secondary to increased 
LDL cholesterol levels. When mice carrying the human CETP gene were cross-bred 
with hyperlipidaemic mice which had a deficiency in either apolipoprotein E or the 
LDL receptor, plasma CETP levels were increased to values higher than those found 
in normolipidaemic mice carrying the human CETP gene (23). However, other 
studies showed that expression of the monkey CETP gene in mice raised plasma 
levels of LDL, a class of lipoproteins which is virtually absent in wild-type mice (24). 
Rats injected intravenously with purified human CETP also showed increased LDL 
and apolipoprotein B concentrations (25). In the present experiment the increase in 
CETP activity levels preceded the increase in LDL cholesterol, as illustrated in figure 
1. This supports a role for CETP in the effect of cafestol on LDL levels in man. 
However, a caveat is in place because triglycerides and presumably VLDL rose 
rapidly on cafestol; thus the rise in CETP may itself have been caused by the rise in 
VLDL. 
PLTP activity also increased upon long term cafetiere coffee consumption. This is 
in agreement with data from our previous study in which subjects consumed coffee 
diterpenes (8). PLTP and CETP belong to the same lipid transfer 
protein/lipopolysaccharide binding protein (LTP/LBP) gene family (26). Both proteins 
are up-regulated by cholesterol feeding in animal studies (27;28), suggesting that 
their genes contain cholesterol-responsive elements (9). A parallel increase in both 
lipid transfer proteins might therefore be expected. Serum LCAT activity levels 
decreased slightly after consumption of cafetiere coffee. A comparable decrease 
was observed earlier after consumption of purified coffee diterpenes (8). Since LCAT 
is solely synthesised in the liver (19), an impairment of liver function, as evident from 
increased activities of serum transaminases after cafetiere coffee consumption (1) 
may explain the decrease in serum LCAT levels. Because LCAT primarily functions 
in the formation of HDL cholesteryl esters, a lower LCAT activity may result in 
decreased HDL cholesterol levels, especially when CETP activity is increased. 
Indeed, cafestol and kahweol were found to lower serum HDL cholesterol in previous 
studies (3;29;30), though not in the present study. 
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If CETP is involved in the mechanism of action of coffee diterpenes then it might 
increase the cholesteryl ester content of VLDL and/or LDL (31). The effect of coffee 
diterpenes on the composition of the various lipoproteins is not known. Two earlier 
studies showed a significant increase in apolipoprotein B100 levels of 0.09 g/L (32) 
and 0.13 g/L (33) after consumption of boiled coffee. This suggests that the increase 
in LDL cholesterol is at least partly explained by changes in the number of LDL 
particles. An additional change in lipoprotein composition can however not be 
excluded. Since the rise in CETP activity preceded the rise in LDL cholesterol upon 
consumption of cafetiere coffee, CETP might contribute to the LDL cholesterol-
raising effect of coffee diterpenes. 
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The coffee diterpene cafestol increases plasma 
triglycerides by increasing the production rate of 
large very low density lipoprotein apolipoprotein B 
in normolipidaemic subjects 
Baukje de Roos, Muriel J. Caslake, Anton F.H. Stalenhoef, Dorothy Bedford, Pierre 
N.M. Demacker, Martijn B. Katan, Chris J. Packard. Submitted. 
Abstract 
Cafestol is a diterpene present in unfiltered coffee that raises plasma triglycerides 
in humans. We studied whether cafestol increases plasma triglycerides by increasing 
the production rate or decreasing the fractional catabolic rate of VLDLi (Svedbergs 
flotation rate 60-400) apolipoprotein B. In addition, we studied the effect of cafestol 
on the composition of VLDLi and VLDL2 (Svedbergs flotation rate 20-60). Eight 
healthy normolipidaemic men were administered a daily dose of 75 mg of cafestol for 
two weeks. A bolus injection of 7 mg/kg of body weight of d3-leucine (L-[5,5,5-
2H3]leucine) was given after a baseline period with no cafestol and again after 
treatment with cafestol. We derived kinetic constants to describe the metabolism of 
VLDLi apolipoprotein B using a multicompartmental model. Cafestol increased 
plasma triglycerides by 31% or 0.32 mmol/L (95%CI [0.03-0.61]). The rise in 
triglycerides was mainly due to a rise in VLDLi triglycerides of 57% or 0.23 mmol/L 
(95%CI [-0.02;0.48]). The pool size of VLDLi apolipoprotein B was increased by 59% 
or 34 mg (95%CI [-1 ;102]). Cafestol increased the mean rate of VLDLi apolipoprotein 
B production by 80% or 755 mg/day (95%CI [0.2;5353]), whereas it did not 
significantly change the mean fractional catabolic rate of VLDLi apolipoprotein B 
(mean increase of 3 pools/day; 95%CI [-4;10]). Cafestol did not change the 
composition of VLDLi. VLDL2 became enriched with cholesteryl esters at the cost of 
triglycerides, as indicated by a significant increase in the VLDL2 cholesteryl 
ester/triglyceride ratio. We conclude that cafestol increases plasma triglycerides by 
an increased production rate of VLDLi apolipoprotein B, probably via an increased 
assembly of VLDLi in the liver. The enrichment of VLDL2 particles with cholesteryl 
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esters - rather than the increased amount of triglyceride-rich VLDLi particles - might 
play a role in the subsequent rise of LDL cholesterol levels. 
Introduction 
Unfiltered coffee brews such as Scandinavian-type boiled coffee, cafetiere (or 
French-press) coffee, and Turkish coffee raise plasma triglycerides and low density 
lipoprotein (LDL) cholesterol concentrations in humans (1). The responsible 
compound is cafestol, a lipid-soluble diterpene in coffee beans (2). Unfiltered coffee 
brews contain 3-6 mg of this diterpene per cup (3). Filtered coffee does not contain 
cafestol, because the diterpene is retained by a paper filter (4). 
In human subjects, the effects of cafestol on plasma triglycerides and on LDL 
cholesterol differ in their kinetics. When 22 volunteers consumed 0.9 L of cafetiere 
coffee per day, plasma triglycerides reached a maximum increase of about 30% after 
2-4 weeks. The effect on triglycerides was transient since levels were back at 
baseline after 24 weeks (5). The onset of the rise in LDL cholesterol was much 
slower: a maximum increase of about 12% was reached only after 8-12 weeks of 
cafetiere coffee consumption. The rise in LDL cholesterol is not transient; 
epidemiological studies show that chronic consumers of boiled coffee have 
permanently elevated levels of plasma cholesterol (6-8). Since the rise in triglycerides 
is the first step in a cascade of changes in lipoprotein metabolism upon consumption 
of cafestol (1;5), this rise might play a role in the subsequent increase in LDL 
cholesterol levels. 
In this study we examined the mechanism by which cafestol increases plasma 
triglycerides in normolipidaemic men. In humans, the majority of triglycerides is 
transported in very low density lipoproteins (VLDL). However, VLDL can be 
fractionated into two structurally and metabolically discrete components: VLDLi (Sf 
60-400) and VLDL2 (Sf 20-60). Compared to VLDL!, VLDL2 are smaller, enriched in 
cholesteryl ester, depleted in triglycerides and have a lower ratio of apolipoprotein E 
and apolipoprotein C to apolipoprotein B (9). There is evidence for an independent 
regulation of the secretion of VLDLi and VLDL2 by the liver (10-13). High levels of 
triglyceride rich VLDLi have been suggested to give rise to a preponderance of small 
dense LDL, which appears - rather than large more buoyant LDL - a risk factor for 
coronary heart disease (9). Since VLDLi carries almost half of the total amount of 
triglycerides in the circulation, whereas VLDL2 carries only about one fifth, we used a 
modelling approach to quantify the kinetic properties of VLDLi apolipoprotein B 
metabolism (14). In addition, we determined the effects of cafestol on VLDLi and 
VLDL2 composition. Our hypothesis was that an increased secretion of VLDLi 
apolipoprotein B into the circulation - i.e. an increased production rate - or a 
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decreased clearance of VI-DI^ apolipoprotein B from the circulation - i.e. a decreased 
fractional catabolic rate - might cause an increased amount of VI-DI^ particles in the 
circulation, either or not enriched with triglycerides, explaining the rise in plasma 
triglycerides upon consumption of cafestol. 
Subjects & methods 
Prior approval for this study was obtained from the Research Ethics Committee of 
the Glasgow Royal Infirmary, University N.H.S. Trust, and the Committee on 
Experimental Research in Humans of the Nijmegen University Hospital. 
Subjects 
Fifty-two men entered a medical screening. All had normal hepatic and renal 
function, and none had haematological abnormalities. No subject was taking any 
medication known to affect lipid metabolism. Eight healthy normolipidaemic men with 
plasma triglyceride levels between 0.9 and 2.0 mmol/L were selected to participate in 
the study. They had a mean (±SEM) age of 21 ±1 years and a mean (±SEM) body 
mass index of 22.30+0.65 kg/m2. Three volunteers had the apolipoprotein E 
phenotype 4/3, three the apolipoprotein E phenotype 3/3, and two the apolipoprotein 
E phenotype 3/2. The first two subjects were studied at the Department of 
Pathological Biochemistry, Glasgow Royal Infirmary, Scotland. The remaining 6 
subjects were studied at the Department of Internal Medicine, Nijmegen Academic 
Hospital, The Netherlands. The subjects were well informed about the purpose and 
protocol of this experiment. They gave their written informed consent before the start 
of the study. 
Preparation of the cafestol supplements and the tracer 
Cafestol esters were hydrolysed and extracted from coffee oil and then re-
esterified with palmitate in the laboratory of the Department of Human Nutrition and 
Epidemiology, Wageningen Agricultural University, The Netherlands. It had a purity 
of 85%; the impurities consisted of free cafestol, cafestol dipalmitate and palmitic 
acid. Cafestol palmitate was dissolved in a mixture of sunflower oil and palm oil (3:2 
by mass). Earlier studies have shown that this mixture of sunflower oil and palm oil 
has no effect on plasma cholesterol levels. The daily amount of cafestol provided in 
this study, i.e. 75 mg cafestol (= 131.5 mg cafestol palmitate) was divided over two 
capsules in order to spread the cafestol uptake over a day. 
D3-leucine (L-[5,5,5-2H3]leucine) with a purity higher than 99% was purchased 
from Cambridge Isotope Laboratory (Woburn, MA). It was dissolved in 0.9% saline to 
a concentration of 10 mg/mL, sterilised and checked for pyrogens. 
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Study design 
Plasma lipids, VLDLi and VLDL2 apolipoprotein B, the production and fractional 
catabolic rates of VLDLi apolipoprotein B, and the composition of VLDLi and VLDL2 
were measured after a cafestol-free baseline period and directly after two weeks of 
treatment with cafestol. We first performed a VLDL turnover study to obtain baseline 
values. For this, subjects were fasted for 12 h overnight. At approximately 8 a.m. the 
tracer d3-leucine was administered as an intravenous bolus injection (7.0 mg/kg of 
body weight). We took plasma samples immediately before tracer injection and at 
multiple time points throughout the following 48 h: at 2, 5, 10, 15, 20, 30, 40, 60, 80, 
120 min; at 3, 4, 6, 8, 10, 11, 14, 24, 36 and 48 h. A total amount of 240 ml_ of blood 
was sampled per VLDL turnover study. To keep the chylomicron production minimal 
during the initial 12-h phase of the turnover, participants were fasted until 6 p.m. and 
were then permitted a light fat-free meal. Blood samples taken after 24 and 48 h 
were also taken in the fasting state. At least two weeks after the first turnover, 
subjects swallowed two capsules with 37.5 mg of cafestol each per day for a period 
of two weeks. On the last two days of this 2-week treatment-period, a second VLDL 
turnover study was performed as described above. The 16 VLDL turnover studies 
were done over a period of nine months. We always performed two turnovers on the 
same occasion; a VLDL turnover after a cafestol-free baseline period in one subject 
was combined with a VLDL turnover after treatment with cafestol in a second subject. 
This will reduce the impact of drifts in the variables of interest with time. 
The subjects did not drink any other coffee than filtered coffee for at least two 
months prior to the start of the experiment. In addition, subjects were not allowed to 
drink any other coffee brews than drip filter coffee, percolated coffee or instant coffee 
throughout the study. During the whole experimental period, subjects were asked to 
maintain their usual pattern of diet and physical activity. Alcohol consumption was 
restricted to a maximum of two units per day. The subjects were asked to record any 
deviation from the usual diet and physical activity in a special diary. In addition, 
subjects were asked to record the time of consuming the capsules with cafestol, the 
daily amount of alcoholic intake, signs of illness, and medications used. 
Plasma lipids and apolipoprotein E phenotype 
We determined plasma cholesterol and triglycerides by enzymatic methods 
(CHOD-PAP and GPO-PAP, respectively, Boehringer-Mannheim, Mannheim, 
Germany, cat no 237574 and no 701912). HDL cholesterol was determined by a 
precipitation method using phosphotungstic/Mg2+ (15). LDL cholesterol was 
calculated as described by Friedewald (16). We isolated total VLDL by 
ultracentrifugation of plasma for 16 hours at 36,000 rpm (168,000 g) using the TFT 
45.6 fixed angle rotor (Kontron, Zurich, Switzerland), in a Beckman L7-55 
ultracentrifuge (Beckman, Palo Alto, California) (17). In this VLDL fraction we 
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analysed total cholesterol and triglycerides as described above. Apolipoprotein E 
phenotypes were determined after iso-electric focusing of VLDL apolipoproteins, as 
described previously (18). Results were periodically checked with apolipoprotein E 
genotyping according to Hixson et al (19). 
Lipoprotein composition and apolipoprotein B pool size 
We isolated VLDLi and VLDL2 from 2 mL of plasma by cumulative flotation 
gradient ultracentrifugation using a six-step discontinuous salt gradient (20;21). The 
lipid composition of the two VLDL subtractions was determined using the methods 
mentioned above for total cholesterol and triglyceride determination. We used 
enzymatic reagents for the determination of free cholesterol and phospholipids 
(Boehringer cat. no. 310328 and 691844, respectively). The amount of cholesteryl 
esters was subsequently calculated as the difference between total and free 
cholesterol. To correct for losses of lipids and protein during ultracentrifugation, we 
multiplied the measured content of lipids and protein in both VLDL subtractions with 
the ratio VLDL triglycerides^VLDL^VLDLa) triglycerides. The mean recovery (±SEM) 
of VLDL1+VLDL2 triglycerides compared to VLDL triglycerides was 70±6% after the 
cafestol-free baseline period and 64±9% after treatment with cafestol. 
We precipitated apolipoprotein B from both VLDL subtractions by addition of an 
equal volume of isopropanol (22). We determined the apolipoprotein B content of 
VLDLi and VLDL2 as the difference between total and isopropanol soluble protein 
(20;22;23). To correct for losses of apolipoprotein B during ultracentrifugation, we 
multiplied the measured apolipoprotein B content with the ratio VLDL 
triglycerides/(VLDL1+VLDL2) triglycerides as described above. VLDLi and VLDL2 
apolipoprotein B pool sizes were calculated as the product of plasma volume 
(assumed to be 4% of the body weight) and the plasma concentration of 
apolipoprotein B in VLDLi and VLDL2. The leucine content of the apolipoprotein B 
pools was assumed to be 12.12% of apolipoprotein B (24). 
D3-leucine enrichment in apolipoprotein B 
The precipitated apolipoprotein B from the VLDLi fraction was delipidated with 
ethanol-ether (3:1) and dried with ether. We subsequently hydrolysed apolipoprotein 
B with 1.0 mL 6 N HCI at 110°C for 24 h (20). 
From plasma, we precipitated proteins with trichloroacetic acid as described (14). 
We determined the enrichment of leucine with d3 -leucine (i.e. the tracer/tracee 
ratio's) in apolipoprotein B hydrolysates and in plasma free amino acids by gas 
chromatography-mass spectrometry (GC-MS) (14). The maximal level of enrichment 
of leucine with d3 leucine is approximately similar in all turnovers. The mean 
tracer/tracee curves are shown in figure 1 (upper panel). Tracer mass was calculated 
by multiplying the tracer/tracee ratio's with the tracee mass (figure 1, lower panel). 
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Figure 1. Mean tracer/tracee in VLDL, apolipoprotein B (upper panel) and incorporation of d3-leucine 
mass into VLDL, apolipoprotein B (lower panel) after a baseline period with no cafestol treatment (O) 
or after a 2-week treatment period with cafestol (9) in eight normolipidaemic men. D3-leucine was 
given as a bolus infusion at time zero. Tracer mass was calculated by multiplying the tracer/tracee 
ratio (as determined by a GC-MS method) with the tracee mass. Bars indicate SEM. In the inserts, the 
tracer/tracee and tracer mass are depicted on a linear scale. 
Kinetic analysis and multicompartments! modelling 
We adapted a model (figure 2) which was developed and described previously 
(14). The first four compartments explain the kinetics of plasma leucine. D3-leucine is 
injected into the plasma compartment (compartment 1). An intracellular pool in the 
liver (compartment 2) is the immediate precursor of the d3-leucine. Compartments 3 
and 4 represent body protein with a slow turnover. Input of leucine into VLDL! 
apolipoprotein B occurs from compartment 2 via a delay compartment (compartment 
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5). The delay indicates the time between the injection of d3-leucine in the plasma 
compartment and its appearance in VLDLi apolipoprotein B. The delay was set at 0.5 
h initially but was adjusted between 0.4 and 0.6 h when required to obtain a better fit 
of the curves. Input of apolipoprotein B into VLDLi occurred at compartment 6. 
Compartments 6 and 7 represent a delipidation chain. Compartment 8 represents a 
remnant particle that does not undergo further delipidation but is eventually 
eliminated from the plasma. 
Before fitting this model to the data, we introduced parameter dependencies to 
prevent that the number of unknown parameters (transfer rate constants) exceeded 
the number of equations. For the plasma kinetics, the transfer rate constants k^2 and 
k2,i were both fixed at 2.5, and the value for k3i4 was set at 0.1*/c4|3. These values 
have been determined in previous studies on long term data in a large group of 
subjects (14). We assumed that the delipidation rate from compartments in VLDLi 
was similar. Therefore, the delipidation rate constants /c76and k0j were made equal. 
These parameter dependencies were applied in all 16 turnover studies. 
The measured data, i.e. the tracer/tracee ratios and the VLDLi apolipoprotein B 
leucine masses, were analysed with the SAAMII program (SAAM institute, University 
of Washington, Seattle, WA). This program derives the value of the kinetic rate 
constants that produce the best fit between the calculated and the measured 
tracer/tracee ratios. Initially, the tracer/tracee ratio's were assigned a standard 
deviation that was related to the precision of their measurement by GC-MS. Previous 
studies have shown that GC-MS analysis of the tracer/tracee values show a 
coefficient of variation (or relative SD) of about 1% (25). Thus, we assumed that the 
SD at the peak value of the tracer/tracee curve, which in our study was typically 
between 0.05 and 0.1, equalled 1% of that peak height. SAAMII subsequently 
calculated a weight for each tracer/tracee ratio, which is the reciprocal of the square 
of the standard deviation assigned to these data. During the fitting process, peak 
values of tracer/tracee were assigned a lower SD, thus more weight, when this would 
lead to a better fit of the model to the data. The weights were adjusted until there was 
no further improvement in the sum of squares. Eventually, we applied a mean 
standard deviation of approximately 3x10"5 to the peak ratio's of VLDLi 
apolipoprotein B leucine, which represented a coefficient of variance of about 0.1%. 
The derived kinetic constants and the transport rates were considered acceptable 
when the calculated curves fitted the observed data without systematic error and 
when the calculated masses for VLDLi apolipoprotein B were within 10% of the 
measured apolipoprotein B pool sizes. 
The VLDLi apolipoprotein B production rate (in mg VLDLi apolipoprotein B/day) 
was calculated from the output from compartment 2 (i.e. ksi2 * the mass of leucine in 
compartment 2). The VLDLi apolipoprotein B fractional catabolic rate (in pools/day) 
was calculated by dividing the sum of outputs from compartments 7 and 8 (i.e. k07 * 
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mass of leucine in compartment 7 and k0,a * mass of leucine in compartment 8; both 
expressed in mg leucine/day) by the VI-DI^ apolipoprotein B mass (i.e. the combined 
masses of leucine in compartments 6, 7 and 8). 
tracer 
*0,8 
Figure 2. Multicompartmental model for apolipoprotein B metabolism. Bolus infusion data were 
analysed with the same model in all 8 subjects. Plasma leucine (compartment 1) receives the d3-
leucine tracer and distributes it to the body protein pools (compartment 3 and 4) and to the intracellular 
precursor pool for apolipoprotein B synthesis (compartment 2). After the delay (compartment 5), the 
tracer appears in VLDL, via compartment 6, and then throughout delipidation in compartment 7, or 
throughout remnant formation in compartment 8. Parameter dependencies were k(2,1)=k(1,2)=2.5; 
k(3,4)=0.1 *k(4,3); k(7,6)=k(0,7). 
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Statistical analysis 
All data are expressed as mean±SEM. We tested whether cafestol increases the 
VLDLi apolipoprotein B production rate or decreases the VLDLi apolipoprotein B 
fractional catabolic rate with a paired two-tailed Student's t-test. In addition, we tested 
whether cafestol affects the cholesteryl ester/triglyceride ratio of VLDLi and VLDL2 
with a paired two-tailed Student's t-test. The variables VLDLi apolipoprotein B mass 
and VLDLi apolipoprotein B production had a skewed distribution and were therefore 
logarithmically transformed before statistical comparisons. 
Results 
Plasma triglycerides and composition of VLDLi and VLDL2 
Cafestol treatment for two weeks increased average total triglycerides by 31% 
(table 1). VLDI-! triglycerides were increased by 57%, whereas VLDL2 triglycerides 
were increased by only 11%. About 72% of the rise in plasma triglycerides was due 
to a rise in VLDLi triglycerides, and an additional 7% could be explained by a rise in 
VLDL2 triglycerides. 
Table 1. Mean plasma lipids before and after a daily dose of 75 mg of cafestol for two weeks in eight 
healthy normolipidaemic men. 
Plasma lipids (mmol/L) 
Triglycerides 
VLDL triglycerides 
VLDL, triglycerides 
VLDL2 triglycerides 
Total cholesterol 
VLDL cholesterol 
LDL cholesterol 
HDL cholesterol 
Baseline 
1.05 
0.61 
0.40 
0.21 
4.08 
0.40 
2.53 
1.16 
Cafestol treatment 
1.37 
0.86 
0.63 
0.24 
4.23 
0.50 
2.62 
1.14 
Treatment effect (95% CI) 
0.32 (0.03 to 0.61) 
0.25 (-0.15 to 0.65) 
0.23 (-0.02 to 0.48) 
0.02 (-0.04 to 0.08) 
0.15 (-0.06 to 0.36) 
0.10 (-0.07 to 0.27) 
0.09 (-0.16 to 0.34) 
-0.02 (-0.11 to 0.07) 
Cafestol increased the VLDL! apolipoprotein B pool size by 59% (figure 3). This 
increase was of the same magnitude as the increase in VLDLi triglycerides, 
suggesting that the composition of VLDLi was not altered (table 2). Indeed, the 
VLDLi cholesteryl ester/triglyceride ratio - an index of particle composition - was not 
significantly changed after cafestol treatment (mean increase of 0.02; 95% CI [-0.09; 
0.05]). 
Cafestol increased the VLDL2 apolipoprotein B pool size by 31% or 32 mg (95%CI 
[-27;90]). This increase was larger than the increase in VLDL2 triglycerides, 
suggesting that VLDL2 was depleted in triglycerides. Indeed, the percentage 
cholesteryl ester in VLDL2 was increased (table 2), which was reflected by an 
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increased VLDL2 cholesteryl esters/triglycerides ratio (mean increase of 0.12; 95% CI 
[0.07;0.16]). 
VLDL, apolipoprotein B VLDL1 apolipoprotein B 
pool size production rate 
(mg) (mg/d) 
250 
200 
150 
100 
50 
baseline cafestol 
mean change 34 mg 
95% CI [-1;103] 
4000 
3000 
2000 
1000 
baseline cafestol 
mean change 755 mg/d 
95% CI [0;5353] 
VLDL1 apolipoprotein B 
fractional catabolic rate 
(pools/d) 
40 
30 
20 
10 
baseline cafestol 
mean change 3 pools/d 
95% CI [-4;10] 
Figure 3. Individual changes in the pool size, the production rate and the fractional catabolic rate of 
VLDL, apolipoprotein B after cafestol treatment for two weeks. The heavy line indicates the mean 
change. 
Production and fractional catabolic rate of VLDLi apolipoprotein B 
Inspection of the tracer mass curves by eye revealed that cafestol treatment 
induced more tracer mass in VLDLi apolipoprotein B due to a more rapid appearance 
(i.e. a higher production rate), whereas this treatment induced only a minor increase 
in the clearance of the tracer from the circulation (figure 1, lower panel). This 
suggested that cafestol increased the amount of VLDLi apolipoprotein B mass, and 
thus the amount of VLDLi particles, mainly because of an increased production rate 
of VLDLi apolipoprotein B. 
Multicompartmental modelling of the tracer/tracee data revealed that cafestol 
treatment elevated VLDLi apolipoprotein B (figure 1, lower panel) by significantly 
increasing the mean production rate of VLDLi apolipoprotein B by 80% (figure 3). 
Cafestol non-significantly increased the mean fractional catabolic rate of VLDLi 
apolipoprotein B by 17% (figure 3). 
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Discussion 
In this study we showed that in healthy normolipidaemic subjects, cafestol 
increased plasma triglycerides mainly by increasing the production rate of VLDLi 
apolipoprotein B. This resulted in an increased amount of VLDLi particles in the 
circulation. Cafestol did not change the composition of VLDLi. VLDL2 became 
enriched with cholesteryl esters at the cost of triglycerides. 
The secretion of apolipoprotein B-containing lipoproteins appears to be regulated 
primarily at a post-translational level, since mRNA levels of apolipoprotein B did not 
change in many situations in which the secretion of apolipoprotein B from cultured 
liver cells was altered over a wide range. The amount of VLDL apolipoprotein B 
reaching the circulation is therefore largely determined by the proportion that 
escapes degradation after the synthesis of the protein (26). Substances like oleate or 
insulin, which are known to affect the secretion of VLDL apolipoprotein B without 
altering its levels of mRNA (27-29), might do this via modulation of VLDLi assembly 
in the liver, which in turn affects the rate at which VLDLi apolipoprotein B is secreted 
into the circulation. Therefore, cafestol might increase the rate at which VLDLi 
apolipoprotein B is secreted into the circulation by increasing the assembly of 
apolipoprotein B with lipids inside liver cells. 
The assembly of apolipoprotein B-containing lipoproteins by the liver is suggested 
to be a 2-step process (figure 4). To initiate lipoprotein assembly, the N-terminal 
portion of apolipoprotein B is thought to be translocated into the lumen of the rough 
endoplasmic reticulum, where it receives a small amount of lipid (whether this is 
cholesteryl ester or triglyceride is still a matter of debate) via the action of microsomal 
triglyceride transfer protein (MTP) (30;31). If this addition of lipid does not occur, or if 
MTP is absent (32), apolipoprotein B may be degraded. Thus MTP appears to control 
the number of apolipoprotein B lipoprotein particles secreted by the liver and thereby 
the apparent production rate of VLDLi apolipoprotein B. Therefore, up-regulation of 
MTP activity is one possible explanation for the increased secretion of VLDLi 
apolipoprotein B upon consumption of cafestol (figure 4). 
In the second step of VLDL assembly, the primordial lipoprotein coalesces with a 
large apolipoprotein B-free droplet of triglycerides at the junction of rough and 
smooth endoplasmic reticulum to form large triglyceride-rich VLDL (figure 4) 
(30;31 ;33). This second step depends on the availability of hepatic triglycerides (34). 
An alternative explanation for the action of cafestol is therefore that it increases the 
availability of triglycerides in the liver by increasing the synthesis of triglycerides or by 
decreasing the rate of (3-oxidation of fatty acids. The rate of p-oxidation of fatty acids 
is modulated by peroxisome proliferator activated receptor a (PPARa) - activity, 
which is however not affected by cafestol (35). Therefore, the two most likely 
mechanisms for the effect of cafestol on VLDLi apolipoprotein B production are that 
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cafestol increases MTP-action or that it increases the synthesis of triglycerides in the 
liver. Both might lead to apolipoprotein B being used for the production of VLDL! 
instead of being broken down. 
CAFESTOL | 
chdesteryl 
ester 
•triglyceride free 
cholesterol 
opoB 
acetyl CoA 
Figure 4. Possible action of cafestol on the assembly of VLDL, in the liver. Cafestol might increase the 
secretion of VLDL apolipoprotein B by increasing the assembly of VLDL,. This effect is possibly 
established by an increased action of MTP and/or by an increased synthesis of triglycerides in the liver 
cell. ApoB: apolipoprotein B; PPARa: peroxisome proliferator activated receptor a; acetyl CoA: acetyl 
coenzyme A; MTP: microsomal triglyceride transfer protein; RER: rough endoplasmic reticulum; SER: 
smooth endoplasmic reticulum. 
Cafestol did not change the composition of VLDLi, but VLDL2 became enriched 
with cholesteryl esters at the cost of triglycerides. This was reflected in a significant 
increase in the VLDL2 cholesteryl ester/triglyceride ratio. Recently, a changed VLDL 
composition upon cafestol treatment has also been found in apolipoprotein E*3-
Leiden transgenic mice (36). VLDL particles became enriched with cholesteryl esters, 
suggestive of the secretion of a (iVLDL-like particle. In this transgenic mouse strain, 
cafestol significantly suppressed bile acid synthesis (36). We hypothesised that the 
cholesterol which comes available in the liver due to inhibition of bile acid synthesis 
might be directly removed via secretion into VLDL particles. Availability of intra-
hepatic cholesterol might therefore be an important regulator of the secretion of 
VLDL2 apolipoprotein B. 
In conclusion, our data indicate that cafestol raises plasma triglycerides 
predominantly by an increased production rate of VLDLi apolipoprotein B after two 
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weeks of intervention. This results in a higher amount of VLDLi particles in the 
circulation. It appears unlikely that this higher amount of VLDLi particles is mainly 
responsible for the subsequent rise in LDL cholesterol. Evidence from kinetic studies 
indicates that only a small part of VLDLi is delipidated to LDL (37;38), whereas 
VLDL2 particles are rapidly and efficiently converted to LDL (37). Therefore, 
cholesteryl ester-enriched VLDL2 particles appear a more likely candidate to play a 
role in the subsequent rise of LDL cholesterol levels. In addition, in vitro studies 
suggest that cafestol elevates plasma LDL cholesterol levels at least partly by down-
regulation of the LDL receptor (39-41). This finding was recently confirmed in vivo in 
apolipoprotein E*3-Leiden transgenic mice (36). Down-regulation of the LDL receptor 
appears to be initiated by a suppression of bile acid synthesis (36;41). The action of 
cafestol on plasma triglycerides and plasma cholesterol might thus be regulated 
independently in the liver. 
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The main objective of this research was to study the mechanism of action of 
coffee diterpenes in humans. The general introduction discussed a number of 
mechanisms that could explain the effect of cafestol on lipoproteins. We 
hypothesised that the most plausible mechanism by which cafestol elevates 
cholesterol in humans appears to be via the sterol regulatory element binding 
proteins (SREBP-) pathway (1). In this chapter we will discuss that the SREBP-
pathway is probably not the only pathway involved in the mechanism of action of 
coffee diterpenes. 
Main outcome from mechanistic studies 
Modulation of bile acid metabolism 
In apolipoprotein E*3-Leiden transgenic mice, cafestol increased serum 
cholesterol concentrations primarily by suppressing the synthesis of bile acids. 
Cafestol decreased the expression and activity of cholesterol 7oc-hydroxylase, and 
the amounts of primary and secondary bile acids in faeces were reduced after 3 
weeks of intervention (chapter 4). 
Is cafestol able to alter bile acid metabolism in humans similarly as in 
apolipoprotein E*3-Leiden mice? Bile acid metabolism in mice is much more easily 
affected by dietary components than that in humans. Mice, who have a high rate of 
hepatic cholesterol synthesis (2), primarily respond to dietary cholesterol by down-
regulation of hepatic cholesterol synthesis and up-regulation of hepatic bile acid 
production. As a consequence, plasma lipoprotein concentrations do not increase as 
easily (3) as in humans, who have a limited ability to activate bile acid synthesis in 
response to dietary cholesterol intake. There are however dietary compounds known 
to affect bile acid metabolism in man. Psyllium, a mucilage from the seeds of 
Plantago ovata, increased faecal excretion of bile acids in man (4). Consumption of 
oat bran increased faecal secretion of bile acids in ileostomy subjects, normo- and 
hyperlipidaemic men, which may explain the concomitant decrease in LDL 
cholesterol (5-8). In analogy, suppression of bile acid synthesis may thus provide an 
explanation for the cholesterol-raising effects of unfiltered coffee in humans. 
In healthy volunteers, consumption of cafetiere (French-press) coffee for 2 
weeks did not significantly affect the secretion of primary (cholic acid and 
chenodeoxycholic acid) and secondary (lithocholic acid, iso-lithocholic acid, 
deoxycholic acid and iso-deoxycholic acid) bile acids in faeces (M. Grubben, 
unpublished results). However, two weeks of treatment with cafestol may be too 
short to detect a significant decrease in faecal output of bile acids. 
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Modulation of the synthesis and composition of VLDL lipoproteins 
In healthy male volunteers, intervention with cafestol for two weeks resulted in a 
significant rise in serum triglycerides. This effect was due to an increased production 
of VLDLi apolipoprotein B, whereas the fractional catabolic rate of this apolipoprotein 
remained unchanged. This resulted in a higher amount of VLDLi particles in the 
circulation. The increased production rate of VLDLi apolipoprotein B might be due to 
an increased activity of microsomal triglyceride transfer protein (MTP) or an 
increased synthesis of hepatic triglycerides. Cafestol did not change the composition 
of VLDLT , but VLDL2 became enriched with cholesteryl esters at the cost of 
triglycerides (chapter 6). 
One determinant of the VLDLi concentration is the VLDLi production rate, which 
has been proposed to be under the influence of hormones. In normoglycaemic 
subjects, insulin suppressed the production of VLDLi apolipoprotein B, without any 
change in the production of VLDL2 (9;10). In post-menopausal women, oestrogen 
treatment resulted in an increased secretion of both VLDLi and VLDL2. In addition, 
oestrogen also increased the fractional catabolic rate of VLDL2 (11). In patients with 
growth hormone deficiency, VLDL apolipoprotein B secretion was increased as 
compared to control subjects (12). Cafestol might be directly responsible for the 
increased production rate of VLDLi apolipoprotein B, but it might as well exert its 
action via modulation of hormones. 
Across a range of plasma lipids, however, the rate of delipidation (e.g. the mass 
transfer from VLDLi into VLDL2) appeared to be the main predictor of plasma 
triglycerides in a population of healthy subjects (C.J. Packard, unpublished 
observations). The conversion of VLDLi to VLDL2 is dependent on lipoprotein lipase 
(LpL), since the fractional transfer rate from VLDLi to VLDL2 is reduced by 90% in 
patients with LpL deficiency (13; 14). LpL activity can be modulated by both 
apolipoprotein C-lll as well as apolipoprotein C-ll (15-17). However, VLDLi has two 
distinct metabolic fates. In addition to being converted to VLDL2, VLDLi lipoproteins 
can also be directly catabolised. It has been proposed that remnant receptors, i.e. 
the LDL receptor-related protein (LRP) or VLDL receptor (18;19), mediate the direct 
removal of large triglyceride-rich VLDL. It appears unlikely that the LDL receptor is 
involved in the direct catabolism of VLDLi, since the rate of VLDLi direct catabolism 
was similar to normal in patients with homozygous familial hypercholesterolaemia 
(20). In our experiment, the plasma- and VLDLi model did not allow us to distinct 
between direct catabolism (via receptor-mediated processes) and transfer to VLDL2 
(via lipolysis). The sum of the two routes, the fractional catabolic rate of VLDLi 
apolipoprotein B, did not appear to be altered by cafestol after two weeks of 
intervention (chapter 6). 
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As proposed in chapter 6, it appears unlikely that an increase in the concentration 
of VLDL! particles upon treatment with cafestol is responsible for the subsequent rise 
in LDL cholesterol. Evidence from kinetic studies in human subjects indicates that 
only a small fraction of VLDLi is delipidated to LDL (13;21), whereas VLDL2 particles 
are rapidly and efficiently converted to LDL (21). Therefore, cholesteryl ester-
enriched VLDL2 particles appear to be a more likely candidate responsible for the 
subsequent rise of LDL cholesterol levels. 
Modulation of cholesterol ester transfer protein (CETP) activity 
Previous studies have shown that dietary compounds that lead to 
hypercholesterolaemia also increase CETP activity in humans (22-26). Cafestol, 
dietary cholesterol, trans- and saturated fatty acids might increase the transfer of 
cholesteryl esters by increasing CETP mass as well as by changing the structure of 
plasma lipoproteins, resulting in better substrates for CETP action. From these 
experiments, it remained unclear whether elevated levels of CETP and phospholipid 
transfer protein (PLTP) are either a cause or a consequence of elevated LDL 
cholesterol levels. We found that cafestol increased CETP activity levels before it 
increased LDL cholesterol levels (chapter 5). This indicates that an increased CETP 
activity during consumption of cafetiere coffee might contribute to the rise in LDL 
cholesterol. However, we also noticed that triglycerides and thus presumably VLDL 
rose rapidly in response to cafestol. Thus the rise in CETP may itself have been 
caused by the rise in VLDL cholesterol or triglycerides. 
CETP mediates the transfer of cholesteryl esters - synthesised by 
lecithinxholesterol acyltransferase (LCAT) - from HDL to the apolipoprotein B-
containing lipoproteins LDL and VLDL (27). The role of CETP in neutral lipid 
exchange and lipoprotein composition is illustrated in humans with a CETP 
deficiency. CETP deficiency is associated with marked hyper-alphalipoproteinaemia 
and a two- to sixfold increase in HDL2. In these patients, HDL lipoproteins are 
increased in size and enriched in cholesteryl esters (28). In addition, the ratio 
cholesteryl ester/triglycerides is decreased in VLDL and IDL lipoproteins (29). In 
human CETP transgenic mice, HDL cholesterol levels and HDL particle size were 
uniformly reduced in three separate studies (30-32). However, it appears that a 
change in CETP activity does not necessarily always have to occur with a change in 
VLDL and IDL/LDL lipoprotein composition. Only in one of these transgenic mice 
studies, VLDL and IDL lipoproteins were enriched with cholesteryl esters (31). In the 
other two studies, CETP activity levels did not or only very modestly changed the 
composition of VLDL and LDL lipoproteins in human CETP transgenic mice (30;32). 
In mechanistic studies on drugs or food substances, the role of CETP in a change 
in lipoprotein composition is difficult to assess. The component of interest might 
change the composition also via the action of for example LCAT, lipoprotein lipase or 
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hepatic lipase. Therefore, changes in the chemical composition of lipoproteins can 
only provide support for a potential mechanism via CETP when more is known on 
the alternative pathways in the mechanism of action of cafestol. At this moment, 
however, we can not exclude a role of CETP in the LDL cholesterol-raising action of 
cafestol. 
Action of cafestol on LDL cholesterol and VLDL triglycerides 
Most in vitro studies suggest that cafestol elevates LDL cholesterol levels by 
down-regulation of the LDL receptor (33-35). This finding was confirmed in vivo in 
apolipoprotein E*3-Leiden transgenic mice (chapter 4). Therefore, increasing 
evidence suggests that a down-regulated LDL receptor activity might, at least in part, 
be responsible for the increased levels of LDL cholesterol. In apolipoprotein E*3-
Leiden mice, down-regulation of the LDL receptor was primarily due to a decreased 
bile acid secretion (figure 1). The SREBP pathway (36) is likely to play an important 
role in this hypothesised mechanism (figure 1). The cholesterol which becomes 
available in the liver due to inhibition of bile acid synthesis might be directly removed 
from the liver as a component of VLDL particles, since we found that VLDL 
lipoproteins in apolipoprotein E*3-Leiden mice and VLDL2 particles in human 
subjects became enriched with cholesteryl esters. As proposed in chapter 6, the 
enrichment of VLDL lipoproteins with cholesteryl esters might also play a role in the 
rise of LDL cholesterol. However, whether cafestol reduces bile acid synthesis in 
humans remains to be established first. 
The effect of cafestol on plasma triglycerides can be explained by an increased 
production rate of VLDLi apolipoprotein B after two weeks of cafestol treatment 
(chapter 6), at which time the increase in plasma triglycerides is maximal (37). The 
initial rise in the production rate of VLDLi apolipoprotein B might be a result of an 
increased activity of MTP or an increased synthesis of hepatic triglycerides, as 
discussed in chapter 6. However, the rise in plasma triglycerides upon cafestol 
treatment is transient, and the liver appears to adapt in a mechanism by which 
triglycerides eventually return to baseline levels. This could be a result of either an 
increased activity of LpL or by a decreased secretion of VLDL triglycerides, which 
might be caused by a depleted store of hepatic triglycerides. We previously 
suggested that once cafestol increased plasma triglycerides, this effect might be 
compensated for by an increased LpL activity. This could explain why triglycerides 
eventually return to baseline after six months of intervention with cafestol (1). 
However, results from studies in apolipoprotein E*3-Leiden mice give evidence for 
the alternative hypothesis. Cafestol caused a maximal increase in serum triglycerides 
after two weeks, after which serum triglycerides rapidly decreased back to baseline. 
After three weeks of intervention with cafestol, when serum triglycerides were on 
their way back to baseline levels, the VLDL triglyceride production rate had 
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decreased by 50%. In addition, we found that hepatic triglycerides had also 
decreased by 50% (chapter 4). A depleted store of hepatic triglycerides might 
therefore explain the return of plasma triglycerides to baseline levels. 
V 
cholesterol 
7cc-hydroxylase 
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lipoprotein 
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Figure 1. Proposed mechanism for the action of cafestol on LDL cholesterol (thick arrows). ACAT: 
acyl-coenzyme A.cholesterol acyltransferase; SREBP: sterol regulatory element binding protein; HMG-
CoA: 3-hydroxy-3-methylglutaryl coenzyme A, 
Validity of animal models 
Data from mechanistic studies on cafestol and kahweol in an animal model may 
provide additional data to support and extend that obtained from human studies. Two 
animal models were tested on their ability to serve as a good model for the 
cholesterol-raising properties of coffee diterpenes in humans. A major criterion of a 
good animal model is that cafestol induces a similar change in lipoprotein profile as 
compared to humans. However, even if the changes in lipoprotein profile of the 
animal model and humans are similar, this alone does not offer proof that the 
mechanisms by which these changes occur are the same. 
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The African green monkey - an animal species that was previously shown to be a 
good model to study the mechanisms of dietary cholesterol and fatty acids on 
lipoprotein metabolism (38-40) - did not appear to be a good model to study the 
mechanism of action of cafestol and kahweol. The response of plasma cholesterol to 
coffee oil was much weaker than in humans. Also, unlike humans, the rise in total 
cholesterol in the monkeys was primarily due to an increase in HDL cholesterol 
rather than LDL cholesterol. 
We also studied the effects of cafestol and kahweol in mice expressing the human 
apolipoprotein E*3-I_eiden gene. Due to the presence of this receptor-defective 
apolipoprotein E variant, the clearance of remnant lipoproteins is impaired in these 
mice. Remnant lipoproteins accumulate in the plasma, and these mice easily 
develop diet-induced hyperlipidaemia and atherosclerosis (41-43). We observed that 
cafestol significantly raised total cholesterol in these mice species. However, the rise 
in total cholesterol was predominantly due to a rise in VLDL and IDL lipoproteins, 
and not in LDL lipoproteins as in humans. Previously, cholesterol feeding also 
induced an accumulation of predominantly cholesterol- and apolipoprotein E-rich 
VLDL remnant lipoproteins in apolipoprotein E*3-Leiden mice (42). The distribution 
of cholesterol among lipoproteins is a major difference between mouse and man. A 
second difference in lipoprotein metabolism is that the mouse edits apolipoprotein 
B100 to the truncated apolipoprotein B48 in both the intestine and the liver, whereas 
in humans apolipoprotein B editing only occurs in the intestine (44;45). Furthermore, 
a mouse lacks CETP as well as lipoprotein (a) (45), two parameters that are both 
affected by cafestol treatment (25;46). These differences should be taken into 
account when results from mice studies are extrapolated to the human situation. 
Human subjects remain preferable for studying the action of cafestol and kahweol, 
but considering the methodological and ethical constraints of mechanistic research in 
humans, the apolipoprotein E*3-Leiden mouse model provides a satisfactory animal 
model. 
Why are we interested in the action of an atherogenic compound? 
Cardiovascular diseases are the leading causes of death in humans in 
industrialised countries. Elevated levels of plasma total or LDL cholesterol (47-49) 
and triglycerides (50-52) are important risk factors for the development of 
atherosclerosis. In the past years, a wide array of cholesterol-lowering drugs has 
been developed by industry, and many studies have been executed to determine 
their mechanisms of action. Then, why would one be interested in determining the 
mechanism of a potentially pro-atherogenic compound? 
First, research on the mechanism of action of both a cholesterol-lowering drug and 
a cholesterol-elevating compound as cafestol can provide insight into the regulation 
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of lipoprotein metabolism in humans. All of the lipid-regulating drugs or food 
compounds that are currently available have a defined role on different aspects of 
controlling serum lipoprotein metabolism (53). Statins lower LDL cholesterol by 
inhibition of 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA), the enzyme for the 
rate limiting step in the synthesis of cholesterol in the liver (53). Fibrates lower 
triglycerides by decreasing the secretion of VLDL, increasing the lipoprotein lipase 
activity and decreasing the release of free fatty acids from peripheral adipose tissue 
via modulation of peroxisome proliferator-activated receptor (PPAR) a (54). Resins 
lower LDL cholesterol by increasing the activity of cholesterol 7a-hydroxylase 
resulting in a higher demand for cholesterol in the liver (55). Dietary plant stanol 
esters reduce LDL cholesterol by inhibition of cholesterol absorption, despite a 
concomitant increase in the synthesis of cholesterol (56). Thus several cholesterol-
lowering drugs as well as cholesterol-elevating or -lowering dietary compounds have 
specific and unique actions on lipoprotein metabolism in humans. Elucidation of the 
mechanism of action of cafestol might be of help in getting insight in the regulation of 
hepatic cholesterol metabolism, and with that in the development of new tools for the 
treatment of abnormal serum lipoprotein levels in humans. 
Second, cafestol is the most potent cholesterol-raising food component known. It 
is almost as potent in increasing LDL cholesterol as the most powerful cholesterol-
lowering drugs are able to lower it. A daily dose of 40 mg of a statin will decrease 
LDL cholesterol by the same percentage as a daily dose of 200 mg of cafestol will 
increase LDL cholesterol (53;57). Relative high amounts of this powerful cholesterol-
raising food component are present in unfiltered coffee brews such as Scandinavian 
boiled coffee, cafetiere (French-press) coffee, Turkish and Greek coffee (58). Boiled 
coffee was once a popular coffee brew in Scandinavia, but nowadays most 
Scandinavians use filtered coffee. This switch in brewing practices is thought to 
explain one third (59) to one half (60) of the 10% fall in serum cholesterol in 
Scandinavia since 1970, and to have contributed significantly to the concurrent fall in 
coronary mortality (61 ;62). On the other hand, cafetiere coffee is gaining popularity in 
many European countries and in the USA. High intakes of cafetiere coffee are likely 
to be associated with an increased risk of coronary heart disease, similar to what has 
been observed with boiled coffee (37;63). Mocha and espresso coffee appear 
harmless with consumption of a few cups per day (57). We do not exactly know how 
much cafestol is present in coffee brews from coffee vending machines. Coffee 
brews from these machines are regularly consumed in public places. Preliminary 
data suggest that the amounts of cafestol in brews from machines that use freeze-
dried coffee are negligible. Amounts of cafestol in brews from machines that use 
suction or pressure ranged from 10 to 100% of the amounts detected in boiled coffee 
(unpublished observations). However, we need to analyse a larger amount of coffee 
brew samples obtained from different types of machines in order to provide a better 
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estimation of the amount of cafestol in brews from coffee vending machines. From a 
public health perspective, patients with high serum cholesterol concentrations or 
patients with an increased risk for ischaemic heart disease should limit their intake of 
cafestol-rich coffee brews. 
Recommendations for further research 
The first mechanistic studies on cafestol have been undertaken, but the major part 
of the action of cafestol in humans is still unknown. This hampers a proper 
extrapolation of more fundamental data from in vitro or in vivo animal studies to the 
human situation. 
Cafestol clearly inhibited bile acid synthesis in apolipoprotein E*3-Leiden mice. As 
was mentioned above, it is of great interest to know how cafestol affects bile acid 
metabolism in humans. A decreased secretion of bile acids by the liver might explain 
the cholesterol-raising properties of coffee diterpenes. It is worthwhile to perform a 
study in which faecal bile acids from subjects treated with cafestol for longer than 2 
weeks are determined with the conventional analysis method, e.g. determination of 
primary and secondary bile acids in freeze-dried faeces after extraction. In addition 
to the measurement of bile acid in faeces, we might be able to detect changes in the 
serum concentration of cholesterol 7oc-hydroxylase (64) upon cafestol treatment. 
We found that cafestol increases the production of VLDU lipoproteins in humans. 
In order to assess if MTP is involved in this action, we might determine the 
expression and activity of MTP in hepatocytes of apolipoprotein E*3-Leiden mice 
after short- and long-term treatment with cafestol. We also found in both humans 
and in apolipoprotein E*3-Leiden mice that cafestol enriches VLDL2 lipoproteins with 
cholesteryl esters at the cost of triglycerides. However, we still do not know how 
cafestol and kahweol affect the composition, the synthesis and catabolism of IDL, 
LDL and HDL lipoproteins. A detailed overview of changes in the lipoprotein profile 
and in apolipoprotein concentrations might help to estimate the atherogenicity of the 
LDL cholesterol-raising effect of unfiltered coffee. 
To elucidate the role of LpL and hepatic lipase activity in lipoprotein metabolism 
during treatment with cafestol, it might be interesting to measure post heparin 
lipolytic activity. This measurement, however, does not provide information on the 
amount of LpL present or the affinity of LpL for lipoproteins. An alternative method to 
measure LpL activity in vivo is to study the triglyceride profiles after an oral fat load 
during several stages of cafestol treatment. Information on levels of VLDL 
apolipoprotein CM - which is required for activation of LpL - and Clll - which inhibits 
LpL activity - might also prove valuable in the assessment of LpL action. 
About 70% of the ingested cafestol and kahweol is absorbed in humans. In order 
to give a more precise estimation of the absorption of coffee diterpenes, we need to 
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know how cafestol and kahweol are metabolised in the human body, and which 
metabolites are subsequently excreted into urine. It is possible that not cafestol itself, 
but a metabolite, is responsible for the cholesterol-raising effect. Attempts to 
measure cafestol in serum might be undertaken in order to estimate the bio-
availability of cafestol. In addition, serum analyses will provide us with an opportunity 
to determine the kinetics and the transport mechanism of cafestol in the circulation. 
Concluding remarks 
Our mechanistic studies suggest that cafestol raises plasma triglycerides and LDL 
cholesterol by separate mechanisms. The mechanism to raise plasma triglycerides is 
relatively rapid, cafestol causing an increase in the production rate of VLDU 
apolipoprotein B. This effect might be a result of an increased MTP activity or by an 
increased synthesis of hepatic triglycerides. The mechanism by which plasma 
triglycerides eventually return to baseline levels in humans is unknown, but a 
depleted store of hepatic triglycerides might play a role in this mechanism. The 
mechanism to raise LDL cholesterol appears to be much slower. Results from both in 
vitro and transgenic mice studies suggest that cafestol increases LDL cholesterol by 
suppression of bile acid synthesis. Subsequently, this might lead to down-regulation 
of the LDL receptor via a decreased activity of SREBP or via an enrichment of VLDL2 
particles with cholesteryl esters. However, whether cafestol or unfiltered coffee brews 
suppress the secretion of bile acids in humans remains to be established. 
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Cafestol and kahweol are diterpenes present in unfiltered coffee brews such as 
boiled or French-press coffee. Cafestol is the most powerful cholesterol-raising food 
substance known. It also causes a transient rise in triglycerides. The mechanism 
through which cafestol influences lipoprotein metabolism is largely unknown. 
Unravelling the mechanism of action might lead to new insights into the regulation of 
serum cholesterol levels in humans. The objective of this thesis was to study the 
mechanism of action of cafestol (and kahweol) in man. 
We first studied the absorption and urinary excretion of cafestol and kahweol in 
man. Absorption values are required to assess which part of the consumed 
diterpenes is actually responsible for the rise in serum lipids. Urinary excretion values 
might provide more insight into the metabolism of cafestol and kahweol in the human 
body. This might lead us to the compound that actually raises serum lipids: the 
diterpenes themselves or a metabolite. Such insights would facilitate further studies 
of the mechanism of action. In this study, nine healthy ileostomists consumed a 
known dose of French-press coffee, after which they collected ileostomy effluent for 
14 hrs and urine for 24 hrs. We measured absorption and urinary excretion of 
diterpenes; their stability was also assessed under simulated gastro-intestinal tract 
conditions. About 90% of the cafestol and kahweol that entered the small intestine 
was absorbed there. Absorption of these coffee diterpenes expressed as percentage 
of the amount consumed was about 70%. Possibly, undetected metabolites were 
present in ileostomy effluent, resulting in lower absorption percentages. We found 
losses of diterpenes during incubation in vitro with gastric juice (about 28%), during 
storage with ileostomy effluent (about 15%), and during freeze-drying (about 29%). 
In conclusion, about 70% of the consumed diterpenes was absorbed in ileostomy 
volunteers, whereas only 1.2% of the diterpenes was excreted as a conjugate of 
glucuronic acid or sulphate in urine. Therefore, these compounds are extensively 
metabolised in the human body (chapter 2). 
We have searched for an animal species in which cafestol and kahweol similarly 
increase plasma cholesterol as in humans. Such an animal model might be a good 
model to study the mechanism of action of these diterpenes. Previous studies 
showed that cafestol and kahweol affected serum lipids in Cebus and Rhesus 
monkeys, hamsters, rats, and gerbils inconsistently and differently than in humans. 
The variability in effects on serum lipids could not be explained by the mode of 
administration or dose of diterpenes, nor by the amount of cholesterol in the diet. 
Therefore, these animal species do not appear to be suitable animal models to study 
the action of coffee diterpenes. Since male African green monkeys show many 
similarities with humans in the effects of dietary cholesterol and fatty acids on plasma 
lipoproteins and cholesterol metabolism, they might be a good model to study the 
effects of cafestol and kahweol on lipoprotein metabolism in man. However, in 
African green monkeys the rise in total cholesterol was less pronounced than in man. 
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Also, unlike humans, the rise in cholesterol was predominantly due to a rise in HDL 
cholesterol rather than LDL cholesterol. Thus, the rise in plasma lipids might illustrate 
the mechanism in these monkeys rather than the mechanism in humans (chapter 3). 
Therefore, the African green monkey does also not appear to be a good model to 
study the mechanism of action of cafestol and kahweol. 
We also determined whether cafestol and kahweol raise serum cholesterol in 
apolipoprotein E*3-Leiden, heterozygous LDL receptor knockout or wild type 
(C57BI/6) mice similarly as in humans. Heterozygous LDL receptor knockout mice 
cannot clear VLDL and LDL particles with the same efficiency as wild type mice - and 
possibly other animal models -, and hence they might be more responsive to 
cafestol. Transgenic mice over-expressing human apolipoprotein E*3-Leiden are 
highly susceptible to diet-induced hyperlipoproteinemia due to a defect in hepatic 
uptake of remnant lipoproteins. A diet with cafestol (0.05% w/w) and kahweol (0.03% 
w/w) increased serum cholesterol by 61% in apolipoprotein E*3-Leiden mice, by 55% 
in LDL receptor knock-out mice and by 46% in wild type mice after eight weeks of 
treatment. The increase in total cholesterol was mainly due to a rise in VLDL and IDL 
cholesterol in all three mouse strains. Since the effects of cafestol and kahweol on 
total cholesterol were most pronounced in apolipoprotein E*3-Leiden mice, we 
subsequently studied the mechanism of action of the diterpenes in this mouse strain. 
After three weeks of treatment, cafestol and kahweol suppressed the major 
regulatory enzymes in the bile acid synthesis pathways: activity of cholesterol 7a-
hydroxylase was reduced by 57% and mRNA levels of cholesterol 7a-hydroxylase 
were reduced by 58%; mRNA levels of sterol 27-hydroxylase were reduced by 32%. 
The total amount of faecal bile acids was decreased by 41%. Cafestol and kahweol 
did not affect hepatic free and esterified cholesterol, but they decreased LDL 
receptor mRNA levels by 37%. VLDL particles contained a three times higher 
amount of cholesteryl esters, indicative for the secretion of a BVLDL-like particle. 
This was confirmed by a decreased rate of VLDL triglyceride production in mice 
treated with cafestol and kahweol (35.1 ±13.8 umol/h/kg) compared to placebo 
treatment (63.1 ±17.5 u.mol/h/kg) as a result of a reduction in hepatic triglyceride 
content by 52%. Therefore, cafestol and kahweol might increase serum cholesterol 
levels by suppression of bile acid synthesis (chapter 4). 
A second study on the mechanism of action of coffee diterpenes was performed in 
humans. We investigated whether the serum lipid transfer proteins CETP and PLTP 
might be involved in the mechanism of action of cafestol and kahweol. In our earlier 
study it remained unclear whether the elevated serum CETP and PLTP activity levels 
were a cause or a consequence of the raised LDL cholesterol concentrations. The 
activity level of the serum enzyme LCAT was studied as well. Forty-six healthy 
normolipidaemic subjects consumed either 0.9 L of French-press coffee or filtered 
coffee for 24 weeks. French-press coffee increased CETP activity by 15% and PLTP 
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activity by 12% after 12 weeks in both male and female subjects. French-press 
coffee decreased LCAT activity by 5% after 12 weeks. Changes in CETP clearly 
preceded the changes in LDL cholesterol. Therefore, we concluded that the 
increased CETP activity during consumption of French-press coffee may contribute 
to the rise in LDL cholesterol (chapter 5). 
We studied whether cafestol increases plasma triglycerides by increasing the 
production rate or decreasing the fractional catabolic rate of VLDLi apolipoprotein B. 
Eight healthy normolipidaemic men consumed a daily dose of 75 mg of cafestol for 2 
weeks. A bolus injection of 7 mg/kg of body weight of d3-leucine (L-[5,5,5-
2H3]leucine) was given as a tracer before and directly after treatment with cafestol. 
We derived kinetic constants to describe the metabolism of VLDLi apolipoprotein B 
using a multicompartmental model. Cafestol increased plasma triglycerides by 31% 
after two weeks of intervention. The rise in plasma triglycerides was mainly due to a 
rise in VLDLi triglycerides. The pool size of VLDLi apolipoprotein B was increased by 
59%. The rise in VLDLi apolipoprotein B was accompanied by an increased VLDLi 
apolipoprotein B production rate of 80%, while the fractional catabolic rate of VLDLi 
apolipoprotein B was not significantly changed. Cafestol did not change the 
composition VLDLi. VLDL2 became enriched with cholesteryl esters at the cost of 
triglycerides. Therefore, cafestol increases serum triglycerides by an increased 
production rate of VLDLi apolipoprotein B. The enrichment of VLDL2 particles with 
cholesteryl esters - rather than the increased amount of triglyceride-rich VLDLi 
particles - might play a role in the subsequent rise of LDL cholesterol levels. 
We conclude that cafestol raises plasma triglycerides and LDL cholesterol by 
separate mechanisms. The initial mechanism to raise plasma triglycerides is a fast 
action, where cafestol causes an increase in the production rate of VLDLi 
apolipoprotein B. The second mechanism by which cafestol increases LDL 
cholesterol appears to be much slower. Results from the studies with apolipoprotein 
E*3-Leiden mice suggest that cafestol increases LDL cholesterol by suppression of 
bile acid synthesis. This might lead to down-regulation of the LDL receptor via a 
decreased activity of sterol regulatory element binding protein (SREBP) and to an 
enrichment of VLDL2 particles with cholesteryl esters. However, whether cafestol or 
unfiltered coffee brews suppress bile acids secretion in humans remains to be 
established. In addition, CETP might as well play a role in the rise of LDL cholesterol 
upon consumption of coffee diterpenes. 
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Cafestol en kahweol zijn stoffen die voorkomen in ongefilterde koffie zoals 
kookkoffie en cafetierekoffie. Van deze twee is cafestol de meest cholesterol- en 
triglyceriden verhogende voedingsstof die we op dit moment kennen. Hoe cafestol 
het cholesterol en triglyceriden gehalte in het bloed van mensen verhoogt is echter 
niet bekend. Het ontrafelen van het werkingsmechanisme zou ons misschien nieuwe 
inzichten kunnen geven in de regulatie van deeltjes die cholesterol en triglyceriden 
vervoeren in het bloed: de lipoproteinen. Er zijn vier verschillende soorten 
lipoproteinen die worden onderscheiden op nun dichtheid: HDL (vervoert het "goede 
cholesterol"), LDL (vervoert het "slechte" cholesterol), IDL (vervoert zowel cholesterol 
als triglyceriden) en VLDL (vervoert voornamelijk triglyceriden). Het doel van dit 
proefschrift is dan ook het bestuderen van het werkingsmechanisme van cafestol. 
Allereest hebben we de opname, omzetting en uitscheiding van cafestol en 
kahweol in het menselijk lichaam onderzocht. Absorptie-waarden zeggen iets over 
het deel van de geconsumeerde cafestol en kahweol dat verantwoordelijk is voor de 
stijging van cholesterol en triglyceriden in het bloed. Informatie over de omzetting 
van cafestol en kahweol in de lever zegt iets over welke stof nu eigenlijk het bloed 
cholesterol en triglyceriden verhoogt: cafestol en kahweol zelf, of misschien een 
afgeleide stof. Deze kennis kan vervolgens helpen bij het oplossen van het 
werkingsmechanisme. Om de aborptie en uitscheiding van cafestol en kahweol te 
bepalen, dronken negen mensen bij het ontbijt een vastgestelde hoeveelheid 
cafetierekoffie, en gedurende de 24 uren hierna hebben we de uitscheiding van 
cafestol en kahweol in stoma-vloeistof en in urine gemeten. Ongeveer 70% van de 
cafestol en kahweol uit de geconsumeerde cafetierekoffie werd geabsorbeerd. 
Cafestol en kahweol werden echter ook afgebroken tijdens hun tocht door het 
maagdarmkanaal en tijdens hun korte verblijf in het stomazakje. We vonden slechts 
1,2% van de geconsumeerde cafestol en kahweol terug in de urine. De omzetting 
van deze stoffen in het lichaam is waarschijnlijk dermate ingewikkeld dat onze 
meetmethoden deze niet kunnen detecteren (hoofdstuk 2). 
We hebben gezocht naar een diersoort waarbij cafestol eenzelfde soort 
cholesterol-verhogend effect veroorzaakt als in mensen. Zo'n diersoort kan 
vervolgens worden gebruikt om het werkingsmechanisme van cafestol en kahweol 
nader te onderzoeken. Voorgaande studies hebben al laten zien dat cafestol en 
kahweol het bloed cholesterol in Cebus en Rhesus apen, hamsters, ratten en gerbils 
niet zo consistent verhogen als in mensen. De verschillen konden hierbij niet worden 
verklaard door de toedieningsvorm, de dosis, of de hoeveelheid cholesterol in het 
voer. In de groene meerkat verhogen cholesterol en vetzuren uit het voer het bloed 
cholesterol op eenzelfde manier als in mensen. Daarom hebben we in deze 
apensoort gekeken of ook cafestol en kahweol op eenzelfde manier het bloed 
cholesterol verhogen als in mensen. We vonden dat beide stoffen het bloed 
cholesterol in deze apen wel verhoogden, maar deze verhoging was aanzienlijk 
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zwakker dan in mensen. Verder veroorzaakten cafestol en kahweol in deze apen 
een ander soort cholesterolstijging: terwijl ze in mensen voornamelijk LDL cholesterol 
verhogen, ging in deze apen juist het HDL cholesterol omhoog. Het cholesterol 
verhogende effect zegt daarom waarschijnlijk meer iets over het 
werkingsmechanisme in deze apen dan over een werkingsmechanisme in mensen 
(hoofdstuk 3). 
We hebben ook het effect van cafestol en kahweol op bloed cholesterol in 
apolipoproteine E*3-Leiden, heterozygote LDL receptor knock-out en wild type 
muizen onderzocht. Cafestol en kahweol verhoogden het bloed cholesterol met 61% 
in apolipoproteine E*3-Leiden muizen, met 55% in LDL receptor knock-out muizen 
en met 46% in wild type muizen na een behandelingsperiode van acht weken. Deze 
verhoging was net als in de apen anders dan in mensen; in deze muizen ging 
voornamelijk het VLDL en IDL cholesterol omhoog. Omdat de respons van het bloed 
cholesterol op cafestol en kahweol het sterkst was in de apolipoproteine E*3-Leiden 
muizen, hebben we vervolgens bij deze muizenstam het werkingsmechanisme van 
cafestol en kahweol nader onderzocht. Na drie weken bleken cafestol en kahweol 
twee enzymen die in de lever zorgen voor de omzetting van cholesterol naar 
galzouten met ongeveer 60% te remmen. De uitscheiding van galzouten in de faeces 
was geremd met 41%. Cafestol en kahweol hadden geen invloed op de hoeveelheid 
cholesterol in de lever, al was de hoeveelheid LDL receptor (een constructie die er 
voor zorgt dat LDL deeltjes uit het bloed in de eel worden opgenomen) verlaagd met 
37%. Cafestol en kahweol verhoogden de cholesterol concentratie in de VLDL 
deeltjes, terwijl de VLDL triglyceriden productie was verlaagd met ongeveer 50% als 
gevolg van een 50% lagere concentratie aan triglyceriden in de lever. Mogelijk is dus 
een remming van de galzuursynthese (mede) verantwoordelijk voor het cholesterol-
verhogende effect van cafestol (hoofdstuk 4). 
In mensen hebben we onderzocht of CETP en PLTP (twee eiwitten die cholesterol 
vanuit HDL deeltjes naar LDL en VLDL deeltjes vervoeren in mil voor triglyceriden) 
zijn betrokken bij het werkingsmechanisme van cafestol. Uit eerder onderzoek bleek 
namelijk niet duidelijk of CETP nu het LDL cholesterol verhoogt of andersom. We 
hebben tevens gekeken naar het effect van cafestol op de aktiviteit van het enzym 
LCAT wat betrokken is bij de aanmaak van HDL deeltjes. Zesenveertig gezonde 
proefpersonen dronken hiervoor gedurende een half jaar lang per dag een 
thermosfles vol cafetiere ofwel filterkoffie. De consumptie van cafetierekoffie 
verhoogde de aktiviteit van CETP in het bloed met 15% en die van PLTP in het bloed 
met 12% na 12 weken in zowel mannen als vrouwen. Na 12 weken was de aktiviteit 
van LCAT in het bloed met 5% gedaald. De stijging in CETP liep duidelijk vooruit op 
de stijging in LDL cholesterol. De stijging in CETP is dus mogelijk betrokken bij het 
LDL cholesterol-verhogende effect van cafetiere koffie (hoofdstuk 5). 
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Veranderingen in de aanmaak- of afbraaksnelheid van grote, lichte VLDL deeltjes 
(deze deeltjes vervoeren relatief de meeste triglyceriden in net bloed) zouden 
kunnen verklaren waarom na het drinken van ongefilterde koffie het triglyceriden 
gehalte in het bloed gaat stijgen. Daarom hebben we gekeken naar het effect van 
cafestol op de kinetiek van grote, lichte VLDL deeltjes in 8 gezonde mannen. 
Cafestol had na 2 weken het triglyceridengehalte in het bloed met gemiddeld 31% 
verhoogd. Cafestol verhoogde daarnaast de hoeveelheid apolipoproteine B eiwit in 
de lichtere VLDL fractie met 59% en de hoeveelheid apolipoproteine B eiwit in de 
zwaardere VLDL fractie met 31%. Omdat elk VLDL deeltje slechts een 
apolipoproteine B eiwit bevat, wijst dit op meer VLDL deeltjes in het bloed. Cafestol 
had geen invloed op de samenstelling van de lichte VLDL deeltjes, terwijl de zware 
VLDL deeltjes relatief meer cholesterol en minder triglyceriden bevatten na 
behandeling met cafestol. Om de kinetiek van de VLDL deeltjes te kunnen 
beschrijven, kregen de proefpersonen voor en na behandeling met cafestol een 
injectie met een gemerkt aminozuur (d3-leucine). Dit gemerkte aminozuur kwam 
terecht in het apolipoproteine B eiwit van de grote, lichte VLDL deeltjes. De snelheid 
waarmee dit gebeurt zegt iets over de aanmaak- en afbraaksnelheid van deze VLDL 
deeltjes. Wij vonden dat cafestol de aanmaak van grote, lichte VLDL deeltjes 
verhoogde, terwijl de afbraaksnelheid niet veranderde. De stijging in de 
aanmaaksnelheid van lichte VLDL deeltjes is dus de oorzaak van de stijging van 
triglyceriden in het bloed na consumptie van cafestol (hoofdstuk 6). 
De conclusie van dit proefschrift is dat een remming van het galzuurmetabolisme 
mogelijk de stijging in LDL cholesterol na consumptie van ongefilterde koffie 
veroorzaakt. We weten echter nog steeds niet goed of mensen na het drinken van 
ongefilterde koffie minder galzuren in de faeces gaan uitscheiden. Dit zou als eerste 
uitgezocht moeten worden. De tijdelijke stijging in triglyceriden wordt veroorzaakt 
door een verhoogde produktie van grote, lichte VLDL deeltjes. Na 4-6 weken zet het 
lichaam waarschijnlijk een compensatie-mechanisme in werking waarmee de 
triglyceriden weer teruggaan naar hun oorspronkelijke niveau. De verhoging in LDL 
cholesterol en triglyceriden wordt mogelijk door twee verschillende mechanismen 
van cafestol veroorzaakt. 
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